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1. Introduction {#sec1}
===============

*Neisseria meningitidis* is a gram-negative diplococcus bacterium that causes meningitis and other meningococcal diseases ([@bib19]; [@bib48]). The bacteria is transmitted person-to-person *via* droplets of respiratory or throat secretions from carriers ([@bib65]). Healthy individuals who have had close and prolonged contact with an infected individual can be infected with the bacteria. For example, closed and prolonged contact such as kissing, sneezing, or coughing or living in close quarters (household crowding), sharing eating or drinking utensils can lead to infection ([@bib19]; [@bib65]). The bacteria colonize the nasopharynx or pharyngeal of carriers ([@bib19]; [@bib27], p. 229; [@bib48]) and can sometimes overwhelm the body\'s defensive system, spreading into the bloodstream and reaching the brain ([@bib19]; [@bib65]). It should be noted that meningococcemia infection state occurs when the bacteria cause a bloodstream infection. About 10% to 20$\text{\%}$ of individuals are estimated to be *Neisseria meningitidis* carriers, but this number may be higher during epidemics outbreaks ([@bib65]). The incubation period of the diseases is about 3--4 days but may vary between 2 and 10 days ([@bib19]; [@bib65]). The fatality rate is about 10%--15%, and the meningococcemia infections can reach up to 40% ([@bib19]).

The meningococcal disease is found worldwide; however, the "meningitis belt" of sub-Saharan Africa has the highest number of occurrences worldwide ([@bib18]). The "meningitis belt" stretches from Senegal to Ethiopia and include countries like Bénin, Burkina Faso, Burundi, Cameroon, Côte d'Ivoire Eritrea, Ethiopia, Gambia, Ghana, Guinea, Guinea Bissau, Kenya, Mali, Mauritania, Nigér, Nigeria, Uganda, Central African Republic, Democratic Republic of Congo, Rwanda, Sénégal, Sudan, South Sudan, Tanzania, Chad, and Togo ([@bib18]; [@bib65]).

The highest incidence of meningitis occurs during the dry season from December to July when dry winds loaded with dust combine with the cold night and the occurrence of upper respiratory tract infection damage the nasopharyngeal mucosa. These combined events increase the risk of meningococcal disease ([@bib17]; [@bib25]; [@bib49]; [@bib65]). Also, *N. meningitidis* transmission could be facilitated by large population displacements and by pilgrimages and traditional markets at regional levels ([@bib49]; [@bib65]). All these factors put together may explain the large epidemics which occurs during the dry Harmattan season in the meningitis belt ([@bib49]; [@bib65]). Harmattan is a season in West African, which happens from November ending to mid-March ([@bib22]; [@bib41]). The season is characterized by the dry and dusty northeasterly trade wind, which blows over West Africa from the Sahara Desert into the Gulf of Guinea ([@bib22]).

There are 12 identified serogroups, 6 of which are known to cause epidemics, these are namely the A, B, C, W135, X and Y serogroups ([@bib19]; [@bib48]; [@bib65]). In Nigeria, *N. meningitidis* strains A and C are the dominant subgroups. A major outbreak of strain A occurred in Nigeria in 2009 with over 55,000 cases which resulted in about 2500 deaths ([@bib67]). And since 2013 Nigeria has been experiencing large outbreaks of meningitis C; in 2015, over 2500 cases of the disease were reported. The current 2017 outbreak has led to over 9902 cases with over 602 deaths ([@bib45]).

*Neisseria meningitidis* is treatable and preventable and vaccines are the cornerstone of prevention and control of the bacteria ([@bib17]). Capsular polysaccharide vaccines used to prevent *N. meningitidis* have been available and used since the 1970s ([@bib17]). These include a bivalent vaccine which prevents the serogroups A and C infections, a trivalent vaccine (against serogroups A, C, and Y) and a tetravalent vaccine (against serogroups A, C, Y, and W135). However, like with any vaccine, meningococcal vaccines are not 100% effective.

In this study, we develop a mathematical model with an imperfect vaccine. We use sensitivity analysis to detect the model parameters whose variability has the strongest impact on the diseases\' reproduction number. From these parameters we select two (namely the use of facial masks and vaccination) and use them as time-dependent control variables. To the best of our knowledge, this study is the first work to uniquely identifies facial masks as means to control *Neisseria meningitidis*. The with the aid of optimal control theory, we investigate the impact of these two variables on diseases transmission, that is, we determine the associated optimal control pair. We also investigate the cost-effectiveness of these control variables using cost-effectiveness analysis.

2. Model formulation {#sec2}
====================

The model is derived as follows: the population is divided into susceptible (*S*), vaccinated (*V*), carrier (*C*), infectious (*I*), and Recovered (*R*) classes. Therefore, the total population at a given is time $N\left( t \right) = S\left( t \right) + V\left( t \right) + C\left( t \right) + I\left( t \right) + R\left( t \right)$.

Individuals move from one class to the other as the disease progresses according to their disease status. The susceptible class (*S*) is populated by new recruits from three classes: 1) either *via* birth or immigration of susceptible individuals at the rate $\text{Π}$; 2) from the recovered individuals with loss of immunity at the rate *κ*;; and 3) from those individuals whose vaccine had waned at the rate *ω*. We further assumed that there is no entry of the infectious into the population either by vertical transmission or immigration; thus, the new inflow into the population does not enter the infectious classes. All individuals, whatever their status, are subject to natural death, which occurs at the rate *μ*. The susceptible population is reduced by infection following effective contact with infected individuals at the rates $\lambda\left( t \right)$, defined by$$\lambda\left( t \right) = \frac{\beta\left\lbrack \eta C\left( t \right) + I\left( t \right) \right\rbrack}{N\left( t \right)}.$$

The parameter *β* is the effective transmission probability per contact and the parameters $\eta \leq 1$ is a modification parameter that indicates the infectivity of individuals in the carrier class. The susceptible population is further reduced by constant vaccination. That is, susceptible individuals, move to the vaccinated class at the constant rate *ν*. Since the meningitis vaccine is highly effective but not 100% effective we assume that the vaccinated population is reduced by infection at the rates $\left( {1 - \varepsilon} \right)\lambda$, where $0 \leq \varepsilon \leq 1.$ The parameter *ε* gives the measure of the vaccine efficacy. For example, $\varepsilon = 1$ indicates that the vaccine is 100% effective. The meningitis vaccine is highly effective but not 100% effective. Thus, we assume that the vaccinated population is reduced by infection at the rates $\left( {1 - \varepsilon} \right)\lambda$, where $0 \leq \varepsilon \leq 1.$ The parameter *ε* gives the measure of the vaccine efficacy. For example, $\varepsilon = 1$ indicates that the vaccine is 100% effective.

When individuals in both susceptible and vaccinated classes are infected they move into the carrier class ($C\left( t \right)$). This class is reduced by disease progression to the infectious class ($I\left( t \right)$) at the rate *σ* or by recovery at the rate $\gamma_{C}$ to the recovered class ($R\left( t \right)$) or by natural death at rate $\mu.$

Individuals in the infectious class increase due to disease activation in the carrier class, the population decreases by recovery at the rate $\gamma_{I}$ and disease-induced death at the rate *δ*. The recovered class is populated by recoveries from both the carrier and infectious classes and reduced due to loss of immunity.

Hence, from the above descriptions and assumptions, the system of nonlinear differential equations describing the transmission dynamics of meningitis in the population is given as$$\begin{array}{l}
{\frac{dS}{dt} = \text{Π} + \omega V + \kappa R - \lambda\left( t \right)S - \nu S - \mu S} \\
{\frac{dV}{dt} = \nu S - \left( {1 - \varepsilon} \right)\lambda\left( t \right)V - \left( {\omega + \mu} \right)V} \\
{\frac{dC}{dt} = \lambda\left( t \right)S + \left( {1 - \varepsilon} \right)\lambda\left( t \right)V - \left( {\sigma + \gamma_{C} + \mu} \right)C} \\
{\frac{dI}{dt} = \sigma C - \left( {\gamma_{I} + \mu + \delta} \right)I} \\
{\frac{dR}{dt} = \gamma_{C}C + \gamma_{I}I - \left( {\mu + \kappa} \right)R,} \\
\end{array}$$

The descriptions of the model parameters are given in [Table 1](#tbl1){ref-type="table"} and the model flow-diagram is given in [Fig. 1](#fig1){ref-type="fig"}.Table 1Description and values of the parameters of the meningitis models (2) and (3).Table 1ParameterDefinitionBaseline valueReference$\text{Π}$Recruitment rate3,253,607 year^−1^Estimated*ν*Vaccination rate0.4868 day^−1^Assumed*ε*Vaccine efficacy85%[@bib64]*ω*Vaccine waning rate1/5 day^−1^([@bib16]; [@bib26])*β*Transmission probability0.3345 day^−1^Fitted*η*Disease modification parameter1Assumed$\gamma_{C}$Recovery rate for carrier0.1118 day^−1^Fitted$\gamma_{I}$Recovery rate for infected0.1128 day^−1^Fitted*σ*Disease progression rate0.0438 day^−1^Fitted*κ*Immunity waning rate0.0032 day^−1^Fitted*μ*Natural death rate1/56 year^−1^[@bib66]*δ*Disease induced death rate0.1923 year^−1^([@bib28]; [@bib61])Fig. 1Flow diagram of the meningitis model (2).Fig. 1

2.1. The basic reproduction number {#sec2.1}
----------------------------------

The basic reproduction number ($\mathcal{R}_{0}$) of the meningitis model (2) is given below. The reproduction number, $\mathcal{R}_{0}$, is the number of secondary infections in an entirely susceptible population due to infections from one introduced infectious individual with meningitis. If $\mathcal{R}_{0} < 1$, the disease will die out in the community and if $\mathcal{R}_{0} > 1$ it will persist. The theoretical study of the model basic properties are presented in [Appendix A](#appsec1){ref-type="sec"}, and the calculations to derive the expression of $\mathcal{R}_{0}$ are given in [Appendix B](#appsec2){ref-type="sec"}.

The reproduction number is given as$$\mathcal{R}_{0} = \frac{\beta\left\lbrack \eta\left( {\gamma_{I} + \mu + \delta} \right) + \sigma \right\rbrack\left\lbrack \omega + \mu + \nu\left( {1 - \varepsilon} \right) \right\rbrack}{\left( {\sigma + \gamma_{C} + \mu} \right)\left( {\gamma_{I} + \mu + \delta} \right)\left( {\omega + \mu + \nu} \right)}.$$

In the absence of vaccine (i.e., $\nu = 0$) $\mathcal{R}_{0}$ reduces to ${\widetilde{\mathcal{R}}}_{0}$ given in equation [(4)](#fd4){ref-type="disp-formula"} below. The quantity ${\widetilde{\mathcal{R}}}_{0}$ is the reproduction number in the worst-case scenario when intervention like vaccination is absent.

2.2. Backward bifurcation {#sec2.2}
-------------------------

Disease transmission models typically undergo a simple transcritical bifurcation at $\mathcal{R}_{0} = 1$ where there is an exchange of model\'s stability as the model equilibria move from the disease-free equilibrium (DFE) to an endemic equilibrium. Some models such as vaccination models, exhibit backward bifurcation where the stable DFE co-exists with a stable endemic equilibrium when the reproduction number is less than unity (see ([@bib1]; [@bib2]; [@bib4]; [@bib10]; [@bib20]; [@bib21]; [@bib24]; [@bib52]; [@bib53])). In a backward bifurcation setting, disease control is only feasible if $\mathcal{R}_{0}$ is reduced further to values below another sub-threshold less than unity.

The important implication of this phenomenon on public health is that the classical requirement of having the reproduction number less than unity, although necessary, is no longer sufficient for disease control. This means that the effective disease control is dependent on the initial sizes of the sub-populations of the model. It is instructive, therefore, to explore whether or not the model (2) exhibits the phenomenon of backward bifurcation. In determining this possibility in the model (2), we use the Centre Manifold theory ([@bib13]), as described in Theorem 4.1 by Castillo-Chavez and Song ([@bib14]).

The existence of the endemic equilibria of the meningitis model (2) is given in [Appendix C](#appsec3){ref-type="sec"}, while the backward bifurcation analysis is given in [Appendix D](#appsec4){ref-type="sec"}.

2.3. Parameter estimation {#sec2.3}
-------------------------

Here we parameterize meningitis model (2). We employ three strategies for obtaining parameter values: first we gather the parameter values from literature (see [Table 1](#tbl1){ref-type="table"}). Second, for those parameter not found in the literature we estimate their values when possible (see [Table 1](#tbl1){ref-type="table"}). For instance, the demographic parameter, *μ*, is estimated as $\mu = 1/56$ *per* year, where 56 years is the average lifespan in Nigeria ([@bib66]). The other demographic parameter, $\text{Π}$, is then estimated as follows. Since the total population of Nigeria as at 2015 was $182,202,000$ ([@bib66]), we assumed that $\text{Π}/\mu$, which is the limiting total human population in the absence of the disease, is $182,202,000$, so that $\text{Π} = 3,253,607$ *per* year.

For those parameters we could not obtain their values by either of the above processes we fitted them based on the 2017 Nigerian meningitis outbreak data obtained from the Nigeria Centre for Disease Control (NCDC) for weeks 5--27 ([@bib43]). However, it should be noted that in the data set no public health interventions such as vaccination were used during weeks 5--27. Thus, to proceed with the parametrization, we develop in the subsection below the basic meningitis model (3) to reflect these conditions. Before we introduce the model, we describe the data set to be used.

### 2.3.1. The 2017 meningitis outbreak data {#sec2.3.1}

The data were obtained from the Nigeria Centre for Disease Control (NCDC) ([@bib43]). The NCDC compiles weekly meningitis epidemiological report data from hospitals in affected States throughout the country. The data include the cumulative number of cases and deaths. [Fig. 2](#fig2){ref-type="fig"} displays the cumulative number of cases from weeks 5 through 27. It should be noted that no public health interventions such as vaccination were used during this period of time.Fig. 2Data fitting of the cumulative new cases and disease-induced mortality using the basic model (3), for the 2017 meningitis outbreaks in Nigeria (extracted from the Nigerian Centre for Disease Control (NCDC) website ([@bib43])). The parameters fitted are given as $\beta = 0.3345,\ \gamma_{C} = 0.1118,\ \gamma_{I} = 0.1128,$$\sigma = 0.0438,\ \kappa = 0.0032$.Fig. 2

### 2.3.2. Basic meningitis model {#sec2.3.2}

To quantify the expected burden of the disease in the country, we fitted the 2017 meningitis data to a meningitis model of a worst-case scenario where public health interventions such as vaccination or facial masks are not implemented in the community. In the absence of such interventions, the model (2) reduces to the following basic model:$$\begin{array}{l}
{\frac{dS}{dt} = \text{Π} + \kappa R - \lambda\left( t \right)S - \mu S} \\
{\frac{dC}{dt} = \lambda\left( t \right)S - \left( {\sigma + \gamma_{C} + \mu} \right)C} \\
{\frac{dI}{dt} = \sigma C - \left( {\gamma_{I} + \mu + \delta} \right)I} \\
{\frac{dR}{dt} = \gamma_{C}C + \gamma_{I}I - \left( {\mu + \kappa} \right)R} \\
\end{array}$$

The meningitis pre-intervention model (3) is bounded and positively-invariant in the biologically-feasible region$$\text{Ω}_{P} \subset \mathbb{R}_{+}^{4},$$with,$$\text{Ω}_{P} = \left\{ {\left( {S\left( t \right),C\left( t \right),I\left( t \right),R\left( t \right)} \right) \in \mathbb{R}_{+}^{4}\ :\ N\left( t \right) \leq \frac{\text{Π}}{\mu}} \right\},$$

The reproduction number for model (3) is given as:$${\widetilde{\mathcal{R}}}_{0} = \frac{\beta\left\lbrack \eta\left( {\gamma_{I} + \mu + \delta} \right) + \sigma \right\rbrack}{\left( {\sigma + \gamma_{C} + \mu} \right)\left( {\gamma_{I} + \mu + \delta} \right)}.$$

The method to derive this expression is similar to the one used to compute $\mathcal{R}_{0}$ (see [Appendix B](#appsec2){ref-type="sec"}) and the calculations are given in [Appendix E](#appsec5){ref-type="sec"}. The global stability of the meningitis model (3) DFE is investigated in [Appendix E](#appsec5){ref-type="sec"} and the existence of the endemic equilibrium is given in [Appendix F](#appsec6){ref-type="sec"}.

To complete the parametrization of the meningitis model (2), we fit the model (3) to the 2017 Nigerian meningitis outbreak data obtained from NCDC for weeks 5--27 ([@bib43]) using the classic least-squares method. Furthermore, The following values were taken for the initial conditions: the initial total population was taken as the population at the year 2015, i.e., $N\left( 0 \right) = 182,202,000;$ the initially infected individuals as $I\left( 0 \right) = 152$, which is the same as the initial number of infected in the data. We assumed $C\left( 0 \right) = 1$ and $R\left( 0 \right) = 0$, so the initial susceptible are $S\left( 0 \right) = N\left( 0 \right) - C\left( 0 \right) - I\left( 0 \right) - R\left( 0 \right)$.

The resulting fitting is shown in [Fig. 2](#fig2){ref-type="fig"}. The resulting fitted parameter values are $\beta = 0.3345,\ \gamma_{C} = 0.1118,\ \gamma_{I} = 0.1128,\ \sigma = 0.0458\ \kappa = 0.0032$. Using these parameter estimates and the expression for the basic reproduction number ${\widetilde{\mathcal{R}}}_{0}$ in equation [(4)](#fd4){ref-type="disp-formula"}, we obtained the value of ${\widetilde{\mathcal{R}}}_{0}$ for the 2017 meningitis outbreak in Nigeria as ${\widetilde{\mathcal{R}}}_{0} \approx 2.9793$.

2.4. Sensitivity analysis {#sec2.4}
-------------------------

The outputs of deterministic models are governed by the model input parameters, which may exhibit some uncertainty in their determination or selection. We employed a global sensitivity analysis to assess the impact of uncertainty and the sensitivity of the outcomes of the numerical simulations to variations in each parameter of the model (2) using Latin Hypercube Sampling (LHS) and partial rank correlation coefficients (PRCC). LHS is a stratified sampling without replacement technique which allows for an efficient analysis of parameter variations across simultaneous uncertainty ranges in each parameter ([@bib9]; [@bib38]; [@bib39]; [@bib51]). PRCC measures the strength of the relationship between the model outcome and the parameters, stating the degree of the effect that each parameter has on the outcome ([@bib9]; [@bib38]; [@bib39]; [@bib51]). Thus, sensitivity analysis determines the parameters with the most significant impact on the outcome of the numerical simulations of the model ([@bib9]; [@bib38]; [@bib40]). To generate the LHS matrices, we assume that all the model parameters are uniformly distributed. Then a total of 1000 simulations of the models *per* LHS run were carried out. The initial conditions used are stated in Section 1.3, the baseline values are given in [Table 1](#tbl1){ref-type="table"}, and the ranges were chosen as 20% from the baseline values (in either direction). The response functions used are the basic reproduction numbers $\mathcal{R}_{0}$ and ${\widetilde{\mathcal{R}}}_{0}$, for model (2) and (3), respectively. The range for *ε* is taken as 85%--100% ([@bib64]).

To identify the parameters with the most significant impact on the reproduction numbers (${\widetilde{\mathcal{R}}}_{0}$ and $\mathcal{R}_{0}$), the model outcomes, we used Latin Hypercube Sampling (LHS) and partial rank correlation coefficients (PRCC) methods. From [Fig. 3](#fig3){ref-type="fig"}, it follows that the parameters that have the most influence on the reproduction numbers are the transmission probability *per* contact (*β*), the recovery rate of the carrier population ($\gamma_{C}$), the vaccine efficacy rate (*ε*), and the disease progression rate (*σ*). Identification of these critical parameters is essential to the formulation of effective control strategies for combating the spread of disease. In particular, the results of this sensitivity analysis suggest that a strategy that reduces the transmission probability *per* contact (i.e., reduces *β*), will adequately mitigate the spread of meningitis in the community. Furthermore, a strategy that increases the vaccine efficacy (increase *ε*) and increases the recovery rates (increase $\gamma_{C}$) will be useful in curtailing the spread of meningitis in the community.Fig. 3PRCC values for the meningitis models (3) and (2), using as response functions: (a) The reproduction number ${\widetilde{\mathcal{R}}}_{0}$; and (b) The reproduction number $\mathcal{R}_{0}$. Parameter values (ranges) used are as given in [Table 1](#tbl1){ref-type="table"}.Fig. 3

2.5. Quantifying the expected disease burden {#sec2.5}
--------------------------------------------

To quantify the expected burden of the disease in the country (under the worst-case and vaccination scenarios), the distribution profile of ${\widetilde{\mathcal{R}}}_{0}$ and $\mathcal{R}_{0}$ is generated, using the parameter values in [Table 1](#tbl1){ref-type="table"} and the parameters in the parameter space generated from the sensitivity analysis.

The results obtained, depicted in [Fig. 4](#fig4){ref-type="fig"}, show the distribution of the reproduction number in the range ${\widetilde{\mathcal{R}}}_{0} \in \left\lbrack 1.7414,3.4624 \right\rbrack$ (with a mean ${\widetilde{\mathcal{R}}}_{0} \approx 2.4754$, suggesting the potential for a larger meningitis outbreaks, where one infected case infects, on average, about 2.4754 others). However, when vaccination program is implemented, the distribution of $\mathcal{R}_{0}$, decreases to $\mathcal{R}_{0} \in \left\lbrack 0.2257,1.1973 \right\rbrack$, with a mean of $\mathcal{R}_{0} \approx 0.5877 < 1$ (indicating the possibility of eliminating the disease with the use of vaccination). It is evident from [Fig. 4](#fig4){ref-type="fig"} that the disease burden associated with the worst-case scenario is three times more than the vaccination case. Furthermore, it is worth noting that for the worst-case scenario, the central 50% of the generated ${\widetilde{\mathcal{R}}}_{0}$ values are concentrated in the interval $\left( {2.2137,2.6960} \right)$, with the median of ${\widetilde{\mathcal{R}}}_{0} = 2.4624$ close to the mean value. For the vaccination case, the central 50% of the generated $\mathcal{R}_{0}$ values are concentrated in the interval $\left( {0.4217,0.7323} \right)$, with the median around $\mathcal{R}_{0} = 0.5737$. These simulations emphasize the importance of vaccination in curtailing meningitis outbreak in Nigeria.Fig. 4The box plot of the reproduction numbers ($\mathcal{R}_{0}$ and ${\widetilde{\mathcal{R}}}_{0}$) for the model (2) and (3). Parameter values (baseline) and ranges used are as given in [Table 1](#tbl1){ref-type="table"}.Fig. 4

Hence, we obtained in this study, that the value of ${\widetilde{\mathcal{R}}}_{0}$ for the 2017 meningitis outbreak in Nigeria is ${\widetilde{\mathcal{R}}}_{0} \approx 2.9793$ (see Section 1.3) and the distribution of the reproduction number is in the range ${\widetilde{\mathcal{R}}}_{0} \in \left\lbrack 1.7414,3.4624 \right\rbrack$ (with a mean ${\widetilde{\mathcal{R}}}_{0} \approx 2.4754$) for the estimated worst-case scenario. Using the parameters in [Table 1](#tbl1){ref-type="table"} with vaccination as a public health intervention, and the formula for $\mathcal{R}_{0}$ in (1.1), we estimated the reproduction number as $\mathcal{R}_{0} = 0.5737$, which is within the estimated interval $\left( {0.4217,0.7323} \right)$.

In the next section, we apply optimal control theory using results from the sensitivity analysis to determine the optimal vaccination control strategy that will effectively curtail the spread of meningitis in the community.

2.6. The optimal control problems {#sec2.6}
---------------------------------

The result of the sensitivity analysis suggests that a control strategy capable of reducing the transmission probability *per* contact (i.e., reduces *β*) will adequately reduce the spread of meningitis in the community. Furthermore, a strategy that increases the vaccine efficacy (increase *ε*) and the recovery rates (increase $\gamma_{C}$ and $\gamma_{I}$) will be effective in curtailing the spread of meningitis in the community.

Among the parameters identified above, the transmission probability *β* is the one that can be easily manipulated. For example, it can be reduced by decreasing the contact between susceptible individuals and infected using personal protection such as wearing of facial mask. Thus, we introduce into the transmission model (2) a time-dependent control variable $u_{m}\left( t \right)$ (representing the use of facial mask) that impacts the transmission probability $\beta.$ Additionally, we assume that everyone in the community wears facial masks regardless of their vaccine status, which affects the transmission probability indirectly. This assumption is akin to the use of bed-nets in some malaria disease models ([@bib2]; [@bib8]; [@bib46]).

However, ensuring adequate compliance might be challenging since these masks might not be too comfortable to wear particularly for long hours due to the "heat inside a facepiece" ([@bib12]; [@bib55]). Nonetheless, these masks can be worn for as long as 8 h ([@bib15]), just as long as sleeping underneath a bednet in a typical night. On the other hand, there are comfortable masks that can be worn with ease and comfort.

We also consider as a time-dependent control variable the vaccination rate ($u_{v}\left( t \right)$) which was previously taken as a constant parameter (*ν*). Although this parameter does not significantly impact the reproduction number $\left( {\widetilde{\mathcal{R}}}_{0} \right)$, we nevertheless consider this parameter as time-dependent variable since the vaccine efficacy (*ε*) have a significant impact on the $\left( \mathcal{R}_{0} \right)$. The incorporation of the time-dependent control variable $u_{m}\left( t \right)$ and $u_{v}\left( t \right)$ into the model (2) yields:$$\begin{array}{l}
{\frac{dS}{dt} = \text{Π} + \omega V + \kappa R - \lambda\left( t \right)S - u_{v}\left( t \right)S - \mu S} \\
{\frac{dV}{dt} = u_{v}\left( t \right)S - \left( {1 - \varepsilon} \right)\lambda\left( t \right)V - \left( {\omega + \mu} \right)V} \\
{\frac{dC}{dt} = \lambda\left( t \right)S + \left( {1 - \varepsilon} \right)\lambda\left( t \right)V - \left\lbrack \sigma + \gamma_{C} + \mu \right\rbrack C} \\
{\frac{dI}{dt} = \sigma C - \left( {\gamma_{I} + \mu + \delta} \right)I} \\
{\frac{dR}{dt} = \gamma_{C}C + \gamma_{I}I - \left( {\mu + \kappa} \right)R,} \\
\end{array}$$where $\lambda\left( t \right) = \frac{\beta\left\lbrack 1 - u_{m}\left( t \right) \right\rbrack\left\lbrack \eta C\left( t \right) + I\left( t \right) \right\rbrack}{N}$, and $N = S + V + C + I + R$.Our goal is to minimize the cost function defined as$$J\left( {u_{m},u_{v}} \right) = \int_{0}^{t_{f}}\left\{ {A_{1}C + A_{2}I + A_{3}u_{m}^{2}\left( t \right) + A_{4}u_{v}^{2}\left( t \right)} \right\} dt$$subject to the differential equation [(5)](#fd5){ref-type="disp-formula"}, where $t_{f}$ is the final time. This performance specification involves minimizing the numbers of carriers and infectious individuals, along with the cost of applying the controls ($u_{m}\left( t \right),u_{v}\left( t \right)$). In this paper, the controls $u_{m}\left( t \right)$, and $u_{v}\left( t \right)$ in the objective functional are quadratic since the costs of these interventions are nonlinear. This assumption is based on previous works suggesting that there are no linear relationships between the effects of interventions and the cost of the intervention of the infective populations. Additionally, such quadratic costs have been frequently used ([@bib30]; [@bib31]; [@bib32]; [@bib33]; [@bib36]; [@bib68]). The coefficients, $A_{i},\ \ i = 1,\cdots,4$, are balancing cost factors or weights on the costs.We seek to find the optimal controls $u_{m}^{\text{*}},u_{v}^{\text{*}}$, such that$$J\left( {u_{m}^{\text{*}},u_{v}^{\text{*}}} \right) = \underset{\mathcal{U}}{\text{min}}\left\{ {J\left( {u_{m},u_{v}} \right)} \right\}$$with the control set defined as,$$\mathcal{U} = \left\{ u_{m}:\left\lbrack 0,t_{f} \right\rbrack\rightarrow\ \left\lbrack a_{m},b_{m} \right\rbrack,\ u_{v}:\left\lbrack 0,t_{f} \right\rbrack\rightarrow\ \left\lbrack a_{v},b_{v} \right\rbrack,\ \ \text{are}\ \text{Lebesgue}\ \text{measurable} \right\},$$where $a_{m},a_{v},b_{m},b_{v}$ are the lower and upper bounds of controls $u_{m}\left( t \right)$, and $u_{v}\left( t \right)$. The derivation of these bounds are discussed in Section [2.1](#sec2.1){ref-type="sec"}.The controls ($u_{m}\left( t \right),u_{v}\left( t \right)$) are a bounded Lebesgue integrable functions ([@bib31]; [@bib68]). The characterization of the controls are given in [Appendix G](#appsec7){ref-type="sec"} and the study shows that the optimal control pair $\left( {u_{m}^{\text{*}},u_{v}^{\text{*}}} \right)$ minimizing $J\left( {u_{m}^{\text{*}},u_{v}^{\text{*}}} \right)$ is given as$$\begin{array}{lll}
{u_{m}^{\text{*}} = \text{min}\left\{ {b_{m},\text{max}\left\lbrack a_{m},\ \ \frac{\beta\left\lbrack S^{\text{*}}\left( {\lambda_{C}^{\text{*}} - \lambda_{S}^{\text{*}}} \right) + \left( {1 - \varepsilon} \right)V^{\text{*}}\left( {\lambda_{C}^{\text{*}} - \lambda_{V}^{\text{*}}} \right) \right\rbrack\left( {\eta C^{\text{*}} + I^{\text{*}}} \right)}{2A_{3}N^{\text{*}}} \right\rbrack} \right\},} & & \\
{u_{v}^{\text{*}} = \text{min}\left\{ \left. b_{v},\text{max}\left\lbrack a_{v},\ \ \frac{S^{\text{*}}\left( {\lambda_{S}^{\text{*}} - \lambda_{V}^{\text{*}}} \right)}{2A_{4}} \right\rbrack \right\} \right..} & & \\
\end{array}$$

2.7. Setting bounds on the controls $u_{m}\left( t \right)$, and $u_{v}\left( t \right)$ {#sec2.7}
----------------------------------------------------------------------------------------

The time dependent control $u_{m}\left( t \right)$ represents personal protection. This control lies between $0 \leq u_{m} \leq 1$. Observe that if $u_{m} = 0$, then the use of personal protection such as facial masks is ineffective while if $u_{m} = 1$ such personal protection measures are 100% effective. Thus, we set the lower bound of the control $u_{m}\left( t \right)$ to $a_{m} = 0$ and the upper bound to $b_{m} = 1$.

The control $u_{v}$ represents vaccination rate. Vaccination rates for many diseases ranges from 0 to 100%. Zero is an indication of lack of vaccination, and 100% implies total vaccination. Although 100% total vaccination is hard to attain, there are instances when this could be possible. For instance, this could occur if available vaccine dosage is more than the targeted population ([@bib37]). Unfortunately, in some communities in sub-Saharan Africa, it is hard to attain $100\text{\%}$ coverage due to factors like economic reasons and displacement from wars. However, $100\text{\%}$ coverage has been achieved for most childhood diseases ([@bib57]). Hence, we assumed that control $u_{v}\left( t \right)$ is bounded above at one (i.e., $b_{v} = 1$) and below at zero (i.e., $a_{v} = 0$); thus $u_{v}\left( t \right)$ lies between zero and one, that is, $0 \leq u_{v} \leq 1,$ where 1 indicates $100\text{\%}$ vaccination rate.

Next, we discuss the numerical solutions obtained from the corresponding optimal control problem consisting of (5) together with (6); the interpretations from various strategies considered and their corresponding implications for diseases control.

3. Numerical simulations {#sec3}
========================

The computations of the optimal controls and state values were performed using a Runge-Kutta method of the fourth order. The algorithm is summarized as follows: first, an initial estimate for the control pair is made. Then the state variables are solved forward in time using the dynamics (5). The results obtained for the state variables are plugged into the adjoint equations (G-2). These adjoint equations with given final conditions (G-4) are then solved backward in time, employing the backward fourth-order Runge-Kutta method. Both the state and adjoint values are then used to update the control (7), and the process is repeated until the current state, adjoint, and controls values converge sufficiently, that is, convergence is achieved within a pre-set tolerance value ([@bib36]).

To illustrate the optimal control strategies, we mimic a small village in one of the affect States in Nigeria. In particular, we consider the population of Zamfara State one of the worse hit states ([@bib43]). The estimated 2011 total population of the state is $3,838,160$ ([@bib63]). We mimic a small village in this state by taking the statewide population and divide it by 1000. That is, the population of this small village is about $3,838.160 \approx 3,838$. To set the initial conditions we split $3,838.160$ into the classes $I,V,C,R,S$ as follows. The initial infected population is $I\left( 0 \right) = 152$, which is the $I\left( 0 \right)$ value in the data set taken from NCDC. We assume that initial population of vaccinated individuals is $V\left( 0 \right) = 191.908 \approx 192$. The initial population of carriers is $C\left( 0 \right) = 479.77 \approx 480$, and the initial recovered population is $R\left( 0 \right) = 383.816 \approx 384$. Hence, the initial susceptible population is calculated as $S\left( 0 \right) = N\left( 0 \right) - V\left( 0 \right) - C\left( 0 \right) - I\left( 0 \right) - R\left( 0 \right) = 2,630.612 \approx 2,631$. For the weight factors we choose $A_{1} = A_{2} = A_{3} = A_{4} = 1.0$. It should be pointed out that the values of the weights used in the simulations are theoretical as they were chosen only to illustrate the control strategies proposed in this paper.

On vaccine efficiency, the World Health Organization indicate that one dose of the vaccine has a short life efficacy ranging from 85% to 100% in older children and adults ([@bib64]). Thus, we set the vaccine efficacy to be $\varepsilon = 0.95$. Additionally, we set the waning rate to be five years post-vaccination because this is the value reported for young adolescents ([@bib16]; [@bib26]). We assume a vaccination rate $\nu = 0.4868$ because this part of the country is experiencing violent attacks by arm bandits and Boko Haram the Islamist terrorist group; as a result, the vaccination rate may be within this range as the local folks and health officials fear for their lives ([@bib42]; [@bib50]). The reproduction number in the absence of intervention is ${\widetilde{\mathcal{R}}}_{0} \approx 2.9793$, this was calculated in Section 1.4 using the estimated and fitted parameter values in [Table 1](#tbl1){ref-type="table"}. This value indicates the epidemic nature of the disease in the population.

The simulations of the state variables of the meningitis model (5), with and without implementing the optimal control is given in [Fig. 5](#fig5){ref-type="fig"}. We have set the simulation period at 180 days to be consistent with the range of days in the data set we have used. Although, simulation period is 15 days more than the number of days from the data; the cumulative number of cases were obtained from the simulated weeks 5 through 27. With optimal control, most of the susceptible populace are either protected or vaccinated from the bacteria (see [Fig. 5](#fig5){ref-type="fig"}(a) and (b)) thereby leading to fewer individuals at the risk of infection (see [Fig. 5](#fig5){ref-type="fig"}(c)) and eventually resulting in fewer individuals recovering from the infection as shown in [Fig. 5](#fig5){ref-type="fig"}(d). This is not the case in the absence of the control strategy. There are more infectious (carrier and infected) individuals present due to the fact that more susceptible are unprotected, that is, they lack either the use of facial mask or vaccination. Consequently, there are more recovered individuals.Fig. 5Simulation results of model (5) with controls. (a) Susceptible individuals; (b) Vaccinated individuals; (c) Infectious individuals (Carrier and Infected); and (d) Recovered individuals.Fig. 5

The corresponding simulated time-dependent controls ($u_{m}\left( t \right)$ and $u_{v}\left( t \right)$) are depicted in [Fig. 6](#fig6){ref-type="fig"}. The time-dependent controls $u_{m}\left( t \right)$ is at the upper bound, $u_{m} = 1$, for about 35 days before decreasing to the lower bound at the end of the simulation period; while the control $u_{v}\left( t \right)$ starts at a lower rate of 0.12 and slowly increase to a maximum of about 0.67 at day 36 and gradually decreasing over time. These results suggest that to prevent an outbreak, individuals in the community should continually wear these facial or surgical masks at the beginning of the season but they should gradually get vaccinated. The result further suggests that vaccination of the populace should be maintained at a relatively low level of 0.67 for about 80 days of the simulation period. Additionally, the results indicate that to maintain the population protected from the diseases, both the vaccination and the personal protection need to be kept at a relatively high level.Fig. 6Simulation results of the control profile of model (5).Fig. 6

In summary, we have introduced into the model two time-dependent control variables to represent the changes in time of personal protection like facial masks and vaccination. We found that the total number infectious (infected and carrier) individuals can be reduced in the community by the application of personal protection time-dependent controls.

3.1. Varying cost weight associated with controls $u_{m}\left( t \right)$ and $u_{v}\left( t \right)$ {#sec3.1}
-----------------------------------------------------------------------------------------------------

In this section, we investigate the effect of varying $A_{3}$ and $A_{4}$. These coefficients are the balancing cost factors or weights on the costs of implementing the controls $u_{m}\left( t \right)$ and $u_{v}\left( t \right)$. Changes in them give a distinct cost of implementing the control strategies.

3.2. Varying the weight $A_{3}$ associated with control $u_{m}\left( t \right)$ {#sec3.2}
-------------------------------------------------------------------------------

First, we vary the weight $A_{3}$ on the control $u_{m}\left( t \right)$ representing the use of personal protection such as facial or surgical masks. We use the weights $A_{3} = 0.10$, $A_{3} = 1.00$, $A_{3} = 10.0$, and $A_{3} = 100$, the weight $A_{4}$ on control $u_{v}$ is kept at the baseline value of one (i.e., $A_{4} = 1$). These costs correspond to the cases with very cheap, cheap, expensive and very expensive facial masks. The solution profiles for the state variables of the model (5) are similar to the profiles depicted in [Fig. 5](#fig5){ref-type="fig"} and are therefore not shown here. The solution profiles are depicted in [Fig. 7](#fig7){ref-type="fig"}.Fig. 7Simulation results of the control profile of model ((5)) using cost weights (a) $A_{3} = 0.10$; (b) $A_{3} = 1.00$; (c) $A_{3} = 10.0$; and (d) $A_{3} = 100$.Fig. 7

[Fig. 7](#fig7){ref-type="fig"} show that as the weight $A_{3}$ increases from low to high (i.e., from cheap to very expensive cost), control $u_{m}\left( t \right)$ decreases from the upper bound to levels very close to the lower bound. Also, vaccine control $u_{v}\left( t \right)$ increases to the upper bound when the weight $A_{3}$ are very high (i.e., very expensive cost). This reciprocal relationship between the weight $A_{3}$ and control $u_{v}\left( t \right)$ help to keep the community protected and the infection low as observed in [Fig. 5](#fig5){ref-type="fig"}.

3.3. Varying the weight $A_{4}$ associated with control $u_{v}\left( t \right)$ {#sec3.3}
-------------------------------------------------------------------------------

Next, we vary the weight $A_{4}$ on control $u_{v}\left( t \right)$ and maintain the weight $A_{3}$ on control $u_{m}$ at the baseline value of one (i.e., $A_{3} = 1$). We use the weights $A_{4} = 0.10$, $A_{4} = 1.00$, $A_{4} = 10.0$, and $A_{4} = 100$. These costs correspond to very cheap, cheap, expensive and very expensive vaccine, respectively. The profile of the control solutions are depicted in [Fig. 8](#fig8){ref-type="fig"}. The solution of the state variables are similar to those observed in [Fig. 5](#fig5){ref-type="fig"} and are also not show here.Fig. 8Simulation results of the control profile of model (5) using cost weights (a) $A_{4} = 0.10$; (b) $A_{4} = 1.00$; (c) $A_{4} = 10.0$; and (d) $A_{4} = 100$.Fig. 8

At low $A_{4}$ values (i.e., $A_{4} = 0.10$) which corresponds to a very low cost of applying the vaccination, the control $u_{v}\left( t \right)$ is usually at the upper bound and above the control $u_{m}\left( t \right)$ on facial mask. However, as $A_{4}$ increases (indicating more expensive vaccination process), the level of the control $u_{v}\left( t \right)$ falls below the control $u_{m}\left( t \right)$.

This reciprocal relation between the weight $A_{4}$ and control $u_{m}\left( t \right)$ is not as strong or obvious as the reciprocal relationship observed for $A_{3}$ and control $\mu_{v}$ (see [Fig. 7](#fig7){ref-type="fig"}). Note, this relationship helps to keep the community protected and the infection low as observed in [Fig. 5](#fig5){ref-type="fig"}.

4. Cost-effectiveness analysis {#sec4}
==============================

Controlling and eradicating diseases in a community can be both labor intensive and expensive. Hence, to determine the most cost-effective strategy to use, it is imperative to carry out a cost-effectiveness analysis. In this section, we apply cost-effectiveness analysis to investigate the cost-effectiveness associated with the use of vaccination and personal protection control strategies, and the associated benefits gained from implementing these controls ([@bib1]; [@bib3]). To this end, we consider the following combination of time-dependent controls making up three control strategies A-C:

1\. Strategy A: combination of $u_{m}\left( t \right)$ and $u_{v}\left( t \right)$

2\. Strategy B: control $u_{m}\left( t \right)$-only while setting $u_{v}\left( t \right) = 0$; and

3\. Strategy C: control $u_{v}\left( t \right)$-only while setting $u_{m}\left( t \right) = 0$.

along with the baseline cost weights $A_{1} = A_{2} = A_{3} = A_{4} = 1.0$. The cost-effective analysis will be implemented using three approaches; namely, the infection averted ratio (IAR), the average cost-effectiveness ratio (ACER) and the incremental cost-effectiveness ratio (ICER) ([@bib1]; [@bib3]).

4.1. Infection averted ratio {#sec4.1}
----------------------------

The infection averted ratio (IAR) is stated as:$$\text{IAR} = \frac{\text{Number}\ \text{of}\ \text{infection}\ \text{averted}}{\text{Number}\ \text{of}\ \text{recovered}}.$$

The number of infection averted is the difference between the total infectious individuals over the simulation period in the absences of control and the total infectious individuals with control. The strategy with the highest ratio is the most cost-effective.

4.2. Average cost-effectiveness ratio (ACER) {#sec4.2}
--------------------------------------------

The average cost-effectiveness ratio (ACER) is calculated against the no intervention scenarios. The ACER is calculated as$$\text{ACER} = \frac{\text{Total}\ \text{cost}\ \text{produced}\ \text{by}\ \text{the}\ \text{intervention}}{\text{Total}\ \text{number}\ \text{of}\ \text{infection}\ \text{averted}}.$$

The total cost produced by the intervention is estimated using the objective function given in (6).

4.3. Incremental cost-effectiveness ratio {#sec4.3}
-----------------------------------------

The incremental cost-effectiveness ratio (ICER) is the additional cost per additional health outcome. We assume that the costs of the various control interventions are directly proportional to the number of controls deployed. To compare two or more competing intervention strategies incrementally, one intervention is compared with the next-less-effective alternative ([@bib1]; [@bib3]). Thus, the ICER is calculated as$$\text{ICER} = \frac{\text{Difference}\ \text{in}\ \text{infection}\ \text{averted}\ \text{costs}\ \text{in}\ \text{strategies}\ \text{i}\ \text{and}\ \text{j}}{\text{Difference}\ \text{in}\ \text{total}\ \text{number}\ \text{of}\ \text{infection}\ \text{averted}\ \text{in}\ \text{strategies}\ \text{i}\ \text{and}\ \text{j}}.$$

The ICER numerator includes (where applicable) the differences in the costs of disease averted or cases prevented, the costs of intervention(s), and the costs of averting productivity losses among others. The ICER denominator, on the other hand, is the differences in health outcomes which may include the total number of infections averted or the number of susceptibility cases that are prevented from becoming carriers or infected.

4.4. Cost-effectiveness analysis: varying weights {#sec4.4}
-------------------------------------------------

Next, we compare the impact of varying the weights $A_{3},\ A_{4}$ on the infection averted ratio (IAR), average cost-effectiveness ratio (ACER), infection averted, and total cost. We use the control weights $A_{3} = 0.10$, $A_{3} = 1.00$, $A_{3} = 10.0$, and $A_{3} = 100$ keeping $A_{4} = 1$, which is the baseline value. Similarly, we use $A_{4} = 0.10$, $A_{4} = 1.00$, $A_{4} = 10.0$, and $A_{4} = 100$ at the baseline value of $A_{3} = 1$. The results of simulations are in [Fig. 9](#fig9){ref-type="fig"}, where the bar graphs of the two weights $A_{3}$ and $A_{4}$ for the different cost-effectiveness metric are plotted together.Fig. 9Simulation results of model (5) using control weights $A_{3} = 0.10$, $A_{3} = 1.00$, $A_{3} = 10.0$, and $A_{3} = 100$ when $A_{4} = 1$, the baseline value (the turquoise colored bars). Similarly, using $A_{4} = 0.10$, $A_{4} = 1.00$, $A_{4} = 10.0$, and $A_{4} = 100$ at the baseline value of $A_{3} = 1$ (the magenta colored bars). (a) Infection averted; (b) Infection averted ratio (IAR); (c) Average cost-effective ratio (ACER); and (d) Total cost.Fig. 9

When the weights are low, the two controls avert more infections (see [Fig. 9](#fig9){ref-type="fig"}(a), the blue bar in the first column of [Fig. 9](#fig9){ref-type="fig"}(a) corresponds to $A_{3} = 0.10$, while the magenta bar is $A_{4} = 0.10$), but with vaccine averting slightly more infections than facial masks. This is clearly shown in Fig. 9(b), where the bar graph of the ratio of the infection averted is plotted for the different weights. Furthermore, from [Fig. 9](#fig9){ref-type="fig"}(a) and (b), we observed that higher weights led to fewer infections being averted.

The results depicted in [Fig. 9](#fig9){ref-type="fig"}(c) and (d) are expected, lower weights are more cost-effective than higher weights; surprisingly, vaccine led to lower cost at higher weights. This is because vaccination offers better protection with fewer infected at the end of the simulation period. Another factor that may explain such a result is our assumption that everyone in the community uses facial masks regardless of their vaccine status.

4.5. Cost-effectiveness analysis: control strategies A-C {#sec4.5}
--------------------------------------------------------

The results of the optimal control simulations of problems (5), and (6) using Strategies A-C are depicted in [Fig. 10](#fig10){ref-type="fig"}. The three control strategies led to a situation in which most of the susceptible population is either protected or vaccinated from the bacteria (see [Fig. 10](#fig10){ref-type="fig"}(a) and (b)). Strategy A produced the most vaccinated; this is because the use of facial mask offers some level of protection to some vaccinated individuals in the population who would have been infected since the vaccine is not 100% effective.Fig. 10Simulation results of model (5) with and without. (a) Susceptible individuals; (b) Vaccinated individuals; (c) Infectious individuals (Carrier and Infected); and (d) Recovered individuals.Fig. 10

Strategy A and B led to fewer infected and recovered while Strategy C resulted in more infected (infectious and carriers) and recovered (see [Fig. 10](#fig10){ref-type="fig"}(c) and (d)). This result shows the impact of the use of facial masks in protecting the entire populace during the outbreak.

The corresponding time-dependent controls ($u_{m}\left( t \right)$ and $u_{v}\left( t \right)$) for strategies A-C are depicted in [Fig. 11](#fig11){ref-type="fig"}. To ensure the level of protection observed in [Fig. 10](#fig10){ref-type="fig"}, the control profiles for Strategy A are required to be complementary (see the red and black solid lines in [Fig. 11](#fig11){ref-type="fig"}) this is because control $u_{m}\left( t \right)$ is required to start at the upper bound for about 37 days before gradually reducing to the lower bound, while control $u_{v}\left( t \right)$ starts at 0.35 and slowly reaching 0.69 in about 39 days. Notice that after 60 days control $u_{v}\left( t \right)$ is high while control $u_{m}\left( t \right)$ is low, hence the reciprocal relationship earlier mentioned.Fig. 11Simulation results of the control profile of model (5).Fig. 11

For Strategies B and C, the controls $u_{m}\left( t \right)$-only and $u_{v}\left( t \right)$-only are required to start and stay at the upper bounds for about 65 and 54 days respectively. Control $u_{m}\left( t \right)$ stays higher at about 0.70 until the end of the simulation period. Thus, when either strategy B or strategy C is in place, to obtain the level of protection observed in the community while using Strategy A, high level of compliance is required for control $u_{m}\left( t \right)$.

### 4.5.1. Infection averted ratio {#sec4.5.1}

Using the parameter values in [Table 1](#tbl1){ref-type="table"}, the IAR for each intervention strategy was determined. [Table 2](#tbl2){ref-type="table"} gives the IAR for the three strategies implemented.Table 2Total infection averted, total cost, IAR and ACER for the intervention strategies A, B, and C.Table 2StrategiesTotal infection avertedTotal CostIARACERStrategy A$4.2784 \times 10^{4}$$6.1820 \times 10^{3}$0.36290.1445Strategy B$4.2751 \times 10^{4}$$6.2039 \times 10^{3}$0.36360.1451Strategy C$3.7159 \times 10^{4}$$1.1769 \times 10^{4}$0.20030.3167

According to this cost-effectiveness analysis method, Strategy B involving personal protection ($u_{m}\left( t \right)$-only with $u_{v}\left( t \right) = 0$) have the highest infection averted ratio and the least total cost; therefore it is the most cost-effective. The next less cost-effective measure is Strategy A involving the combination of personal protection ($u_{m}\left( t \right)$) such as the use of facial or surgical masks and vaccination ($u_{v}\left( t \right)$). Strategy C involving vaccination of susceptible individuals in the community is the least cost-effective. This is due to the relatively low number of infection averted and a higher total cost (see [Table 2](#tbl2){ref-type="table"}).

### 4.5.2. Average cost-effectiveness ratio (ACER) {#sec4.5.2}

Based on this cost-effectiveness approach, the most cost-effective strategy is Strategy B, followed by Strategy A and the least cost-effective strategy is Strategy C (see [Table 2](#tbl2){ref-type="table"}).

Next, to further investigate the cost-effectiveness of the distinct control strategies, we evaluate the incremental cost-effectiveness ratio (ICER).

### 4.5.3. Incremental cost-effectiveness ratio. {#sec4.5.3}

To implement the ICER, we simulate the model for each of the three interventions strategies. Using these simulation results, we rank the control strategies in increasing order of effectiveness based on infection averted. This ranking procedure shows that Strategy C averted the least number of infections, followed by Strategy A, and Strategy B averts the most number of infections (see [Table 3](#tbl3){ref-type="table"}).Table 3Total infection averted, total cost, and ICER for the intervention strategies A, B, and C.Table 3StrategiesTotal infection avertedTotal CostICERStrategy C$3.7159 \times 10^{4}$$1.1769 \times 10^{4}$0.20030.3167Strategy B$4.2751 \times 10^{4}$$6.2039 \times 10^{3}$0.36360.1451Strategy A$4.2784 \times 10^{4}$$6.1820 \times 10^{3}$0.36290.1445

The ICER is computed as follows:$$\text{ICER}\left( \text{C} \right) = \frac{1.1769 \times 10^{4}}{3.7159 \times 10^{4}}\ \  = \ 0.3167$$$$\text{ICER}\left( \text{B} \right) = \frac{6.2039 \times 10^{3} - 1.1769 \times 10^{4}}{4.2751 \times 10^{4} - 3.7159 \times 10^{4}}\ \  = \ \  - 0.9951.$$$$\text{ICER}\left( \text{A} \right) = \frac{6.1820 \times 10^{3} - 6.2039 \times 10^{3}}{4.2784 \times 10^{4} - 4.2751 \times 10^{4}}\ \  = \ \  - 0.6636$$

A look at [Table 3](#tbl3){ref-type="table"} shows a cost saving of 0.3167 for Strategy B over Strategy C; this is obtained by comparing ICER(B) and ICER(C). The lower ICER obtained for Strategy B is an indication that Strategy C strongly dominate Strategy B; this simply indicates that Strategy C is more costly to implement than Strategy B. Therefore, it is better to exclude Strategy C from the set of control strategies and consider alternative interventions to implement in order to preserve limited resources. Therefore, Strategy C is left out, and Strategy A is further compared with Strategy B. Hence, we obtain the following numerical results.

The ICER is computed as follows:$$\text{ICER}\left( \text{B} \right) = \frac{6.2039 \times 10^{3}}{4.2751 \times 10^{4}}\ \  = \ \  - 0.1451.$$$$\text{ICER}\left( \text{A} \right) = \frac{6.1820 \times 10^{3} - 6.2039 \times 10^{3}}{4.2784 \times 10^{4} - 4.2751 \times 10^{4}}\ \  = \ \  - 0.6636$$

From [Table 4](#tbl4){ref-type="table"} we observe that Strategy B strongly dominate Strategy A. This merely implies that Strategy B is more costly and less effective compared to Strategy A. Thus, we exclude strategy B from further consideration.Table 4Total infection averted, total cost, and ICER.Table 4StrategiesTotal infection avertedTotal CostICERStrategy B$4.2751 \times 10^{4}$$6.2039 \times 10^{3}$0.36360.1451Strategy A$4.2784 \times 10^{4}$$6.1820 \times 10^{3}$0.36290.1445

Thus, following the above analysis, we conclude that Strategy A (control $u_{m}$ and $u_{v}$) is the most cost-effective strategy followed by Strategy B, the combination of all controls $u_{m}$-only. Strategy C (control $u_{v}$-only) is the least cost-effective strategy and should carefully be considered for implementation particularly in resource-limited places such as most of the communities in the meningitis belt of sub-Saharan Africa.

5. Discussions and conclusions {#sec5}
==============================

5.1. Discussions {#sec5.1}
----------------

There are several different serogroups of *Neisseria meningitidis* but only strain A, B, C, W135, X, and Y can cause epidemics ([@bib65]). The dominant strains in Nigeria are strains A and C (Men A and C). Nigeria experienced a major outbreak of strain A in 2009 with over 55,000 cases which resulted in about 2500 deaths ([@bib67]). And since 2013, there have been reported outbreaks of meningitis C in few local government areas of Kebbi and Sokoto States in Nigeria. However, in 2015, over 2500 cases of the disease were reported across three states of the country. And the current 2017 outbreak has led to over 9902 suspected cases and 602 deaths in 31 states of the country ([@bib45]). In future work, we will study the co-evolution of Men A and C in Nigeria and the possible displacement of Men A by Men C.

Vaccine is a highly effective control strategy against the disease, and "can drastically reduce the magnitude of the epidemic" ([@bib67]). Individuals in the meningitis belt have seen some level of protection against Men A by the use of Men A conjugate vaccine (MACV) introduced in 2010 ([@bib67]). Over 260 million people have been vaccinated across 19 countries leading to over 57% reduction in meningitis cases. Unfortunately, this is not the case with Men C ([@bib58]; [@bib67]). The Men C vaccines are polysaccharide vaccines and are currently in short supply because they are being phased out in other parts of the world ([@bib67]). And the more effective and long-lasting conjugate vaccines are not readily and promptly available ([@bib67]).

Hence, it is not surprising to note that during the 2017 meningitis outbreak Nigeria experienced meningitis vaccine shortage ([@bib11]; [@bib42]; [@bib44]; [@bib62]). However, the Nigerian health ministry has been working closely with WHO, UNICEF and other partners to ensure timely access to the Men C vaccines needed to respond to the outbreak and prevent further cases ([@bib44]).

Thus, to ensure the protection of the population, particularly people living in hard-to-reach areas of the region, we propose the use of facial masks. This study is the first study to identify and use facial masks as a means to control *Neisseria meningitidis*. As observed from our sensitivity analysis to adequately reduce the spread of meningitis in the community, it is vital to reduce the transmission probability per contact (i.e., reduce *β*). This can be achieved through the use of measures like the wearing of facial or surgical masks. The idea of such control measure is analogous to the use of insecticide-treated bednets that has drastically reduced the number of malaria cases across sub-Sahara Africa.

The use of facial masks is a personal protection measure used as an infection-control strategy ([@bib59]; [@bib54]). It creates a physical barrier against potential contaminants in the immediate environment and prevents liquid and airborne particles from contaminating the face ([@bib59]). Facial masks can offer up to 45% protection under pseudo-steady concentration environment, while the protection varied from 33 to 100% under expiratory emissions ([@bib34]). The use of surgical and N95 masks against the transmission of SARS has an effective level of about 68% and 91%, respectively ([@bib29]; [@bib54]).

Thus, in this study, we consider not only vaccination but also the use of personal protection like wearing facial masks. We model these control measures by introducing into the meningitis model two time-dependent control variables. We investigated the associated benefits of the control strategies using cost-effectiveness analysis. This was achieved, using three approaches, namely the infection averted ratio (IAR), the average cost-effectiveness ratio (ACER) and the incremental cost-effectiveness ratio (ICER).

Using these cost analysis techniques, we determine the impact of $A_{3},$ and $A_{4}$ (which are the weights on the cost of implementing the controls $u_{m}$ and $u_{v},$ respectively) on IAR, ACER, infection averted, and total cost. The following values of weights were used: $A_{3} = A_{4} = 0.10,A_{3} = A_{4} = 1.00,A_{3} = A_{4} = 10.0$, and $A_{3} = A_{4} = 100$. The results are summarized in [Fig. 9](#fig9){ref-type="fig"}. These costs represent very cheap, cheap, expensive and very expensive facial masks and vaccines respectively. From [Fig. 9](#fig9){ref-type="fig"}(a) and (b) we observed that lower weights could lead to fewer infections; with vaccine averting slightly more infections than the use of facial masks. Furthermore, both controls ($u_{m}$ and $u_{v}$) are equally cost-effective at lower weights than higher weights (see [Fig. 9](#fig9){ref-type="fig"}(c) and (d)). It is surprising to see that facial mask control lead to higher ACER and total cost at higher weights. This is due to the model requirement that everyone in the population uses facial masks regardless of whether they are vaccinated or not. This requirement follows from the model assumption that the meningitis vaccine is imperfect.

According to the results from our analysis, the use of facial masks is comparable to a control strategy implementing vaccination, as it can avert a large number of infections in the communities most impacted by meningitis (See [Fig. 10](#fig10){ref-type="fig"}). The wearing of facial masks is not common in Africa as opposed to a common practice in Asia; nevertheless, the governments of communities in sub-Sahara Africa should consider complementing the use of vaccine with the use of facial masks. Particularly in hard-to-reach villages and especially during outbreaks like the 2017 outbreak in Nigeria. Furthermore, our study shows that the use of low-cost facial masks is very cost-effective (See [Fig. 9](#fig9){ref-type="fig"}). Therefore, the government of communities with limited resources should encourage their citizens to wear these masks, since they will benefit tremendously from saved resources that can be channeled into other projects of equal relevance for the communities.

Further cost analyzes were carried out on the three control strategies A-C using the baseline weights $A_{1} = A_{2} = A_{3} = A_{4} = 1$. Strategy A is a combination of time-dependent controls $u_{m}\left( t \right)$ and $u_{v}\left( t \right)$ representing the use of facial masks and vaccination. Strategy B involves control $u_{m}\left( t \right)$-only, that is, the use of facial mask only while setting $u_{v}\left( t \right) = 0$; and Strategy C is control $u_{v}\left( t \right)$-only, that is, only consider the implementation of vaccination with $u_{m}\left( t \right) = 0$.

Based on the results of these cost analysis, Strategies A and B averted the most number of infection; Strategy C performed the least in averting the number of infections, which is not a surprising result. Similar conclusions follow from the result obtained using the ACER, the IAR, and the objective functional (see [Fig. 9](#fig9){ref-type="fig"}(d) at the baseline weights). Thus, our results suggest that Strategy A is the most cost-effective strategy to implement. Although this analysis shows that Strategy C is the least cost-effective strategy to implement, it still did an excellent job of averting infection in the community (see [Fig. 9](#fig9){ref-type="fig"}(a) and (b)).

In summary, the result of the cost-effectiveness analysis suggests that resource-limited communities such as those in the meningitis belt should consider using facial or surgical masks during the seasons when the prevalence of meningitis is high.

5.2. Conclusions {#sec5.2}
----------------

Next, we summarize some of the main theoretical and epidemiological findings of this study. In this work, we presented a deterministic model of a system of ordinary differential equations of meningitis infection transmission dynamics. The developed model was parameterized using data obtained from Nigerian centers for diseases and controls (NCDC). Optimal control theory was used to study the impact of personal protection (such as facial or surgical masks), and vaccination as effective control measures against the epidemics. The following results were observed from our analysis and numerical simulations:(i)The model has a disease-free equilibrium (DFE) that is locally asymptotically stable if the reproduction number is less than one ($\mathcal{R}_{0} < 1$) and unstable otherwise ($\mathcal{R}_{0} > 1$);(ii)The application of time-dependent controls can reduce the total number of infected (infectious and carrier) individuals in the population;(iii)By investigating the effect of changes in the weights $A_{3},$ and $A_{4},$ which corresponds to changes in the costs of implementing the controls $u_{m}$ and $u_{v},$ we observed that(a)A reciprocal relation exist between the cost of facial mask use and vaccination coverage; as the cost of facial mask increases the use of vaccination increases and *vice versa.*(b)Lower weights are more cost-effective than higher weights.(c)When the weights on the costs are low, the two controls avert more infections, but vaccine averts slightly more infections than facial masks.(iv)The most efficient and cost-effective control strategy is the strategy involving both control variables (that is, Strategy A). This is followed by Strategy B (a strategy with the use of facial masks only). The Strategy C (a strategy with vaccination only) is the least cost-effective. Although vaccination strategy is not cost-effective, it performs just as well as the other two strategies when the ability to curtail the infection is assessed.
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A. Analysis of the meningitis model (2) {#appsec1}
=======================================

Basic qualitative properties {#appsec1.1}
----------------------------

### Positivity and boundedness of solutions {#appsec1.1.1}

For the meningitis model (2) to be epidemiologically meaningful, it is essential to prove that all its state variables are non-negative for all time. In other words, solutions of the model system (2) with non-negative initial data will remain non-negative for all time $t > 0$.Lemma A.1*Let the initial data* $F\left( 0 \right) \geq 0$ *, where* $F\left( t \right) = \left( {S\left( t \right),V\left( t \right),C\left( t \right),I\left( t \right),R\left( t \right)} \right)$*. Then the solutions* $F\left( t \right)$ *of the meningitis model (*2*) are non-negative for all* $t > 0$*. Furthermore*$$\underset{t\rightarrow\infty}{\text{lim}\ \text{sup}}N\left( t \right) \leq \frac{\text{Π}}{\mu},$$where $N\left( t \right) = S\left( t \right) + V\left( t \right) + C\left( t \right) + I\left( t \right) + R\left( t \right).$ProofLet $t_{1} = \text{sup}\left\{ \left. t > 0:F\left( t \right) > 0 \in \left\lbrack 0,t \right\rbrack \right\} \right.$. Thus, $t_{1} > 0$. It follows from the first equation of system (2), that$$\frac{dS}{dt} = \text{Π} + \omega V + \kappa R - \lambda\left( t \right)S - \left( {\nu + \mu} \right)S$$which can be re-written as$$\frac{d}{dt}\left\{ {S\left( t \right)exp\left( {\int_{0}^{t_{1}}{\lambda\left( \zeta \right)d\zeta + \left( {\nu + \mu} \right)t}} \right)} \right\}\  = \left( {\text{Π} + \omega V + \kappa R} \right)exp\left( {\int_{0}^{t_{1}}{\lambda\left( \zeta \right)d\zeta + \left( {\nu + \mu} \right)t}} \right)$$

Hence,$$\begin{array}{l}
{S\left( t_{1} \right)exp\left( {\int_{0}^{t_{1}}{\lambda\left( \zeta \right)d\zeta + \left( {\nu + \mu} \right)t_{1}}} \right) - S\left( 0 \right) = {\int_{0}^{t_{1}}\left\lbrack \text{Π} + \omega V\left( p \right) + \kappa R\left( p \right) \right\rbrack}} \\
{\times \ \ \ exp\left( {\int_{0}^{p}\left. \lambda\left( \zeta \right)d\zeta + \left( \nu + \mu \right)p \right)dp} \right.} \\
\end{array}$$so that,$$\begin{array}{l}
{S\left( t_{1} \right) = S\left( 0 \right)\ exp\left\lbrack - \left( {\int_{0}^{t_{1}}{\lambda\left( \zeta \right)d\zeta + \left( {\nu + \mu} \right)t_{1}}} \right) \right\rbrack} \\
{+ \ \ \ exp\left\lbrack {- \left( {\int_{0}^{t_{1}}{\lambda\left( \zeta \right)d\zeta + \left( {\nu + \mu} \right)t_{1}}} \right)} \right\rbrack{\int_{0}^{t_{1}}\left\lbrack \text{Π} + \omega V\left( p \right) + \kappa R\left( p \right) \right\rbrack}} \\
{\times \ \ \ exp\left\lbrack \left( {\int\limits_{0}^{p}\lambda\left( \zeta \right)d\zeta + \left( \nu + \mu \right)p} \right) \right\rbrack dp} \\
{> \ \ 0.} \\
\end{array}$$

Similarly, it can be shown that $F > 0$ for all $t > 0$.

For the second part of the [Proof](#enun_Proof_4){ref-type="statement"}, note that $0 < S\left( 0 \right) \leq N\left( t \right),0 \leq V\left( 0 \right) \leq N\left( t \right),0 \leq C\left( 0 \right) \leq N\left( t \right),0 \leq I\left( 0 \right) \leq N\left( t \right),0 \leq R\left( 0 \right) \leq N\left( t \right)$.

Adding components of the model (2) gives$$\begin{matrix}
{\frac{dN\left( t \right)}{dt} = \text{Π} - \mu N - \delta I} \\
{\quad \leq \quad\text{Π} - \mu N} \\
\end{matrix}$$

Hence,$$\underset{t\rightarrow\infty}{\text{lim}\ \text{sup}}N\left( t \right) \leq \frac{\text{Π}}{\mu}$$as required.

Invariant regions {#appsec1.2}
-----------------

The meningitis model (2) will be analyzed in a biologically-feasible region as follows. Consider the feasible region$$\text{Ω} \subset \mathbb{R}_{+}^{5},$$with,$$\text{Ω} = \left\{ {\left( {S\left( t \right),V\left( t \right),C\left( t \right),I\left( t \right),R\left( t \right)} \right) \in \mathbb{R}_{+}^{5}\ :\ N\left( t \right) \leq \frac{\text{Π}}{\mu}} \right\},$$Lemma A.2*The region* $\text{Ω} \subset \mathbb{R}_{+}^{5}$ *is positively-invariant for the model (*2*) with non-negative initial conditions in* $\mathbb{R}_{+}^{5}$*.*ProofIt follows from summing equations of model (2) that$$\begin{matrix}
{\frac{dN\left( t \right)}{dt} = \text{Π} - \mu N - \delta I} \\
{\quad \leq \quad\text{Π} - \mu N} \\
\end{matrix}$$

Hence, $\frac{dN\left( t \right)}{dt} \leq 0$, if $N\left( 0 \right) \geq \frac{\text{Π}}{\mu}$. Thus, $N\left( t \right) \leq N\left( 0 \right)e^{- \mu t} + \frac{\text{Π}}{\mu}\left( {1 - e^{- \mu t}} \right)$. In particular, $N\left( t \right) \leq \frac{\text{Π}}{\mu}$.

Thus, the region $\text{Ω}$ is positively-invariant. Furthermore, if $N\left( 0 \right) > \frac{\text{Π}}{\mu}$, then either the solutions enters $\text{Ω}$ in finite time, or $N\left( t \right)$ approaches $\frac{\text{Π}}{\mu}$ asymptotically. Hence, the region $\text{Ω}$ attracts all solutions in $\mathbb{R}_{+}^{5}$.

B. Stability of disease-free equilibrium (DFE) and the reproduction number $\mathcal{R}_{0}$ of the meningitis model (2) {#appsec1.3}
------------------------------------------------------------------------------------------------------------------------

In this section, the conditions for the stability of the equilibria of the model (2) are stated. The meningitis model (2) has a disease free equilibrium (DFE). The DFE is obtained by setting the right-hand sides of the equations in the model (2) to zero, which is given by$$\begin{array}{l}
{\mathcal{E}_{0} = \left( {S^{\text{**}},\ V^{\text{**}},\ C^{\text{**}},\ I^{\text{**}},\ R^{\text{**}}} \right)} \\
{= \left( {\frac{\left( {\omega + \mu} \right)\text{Π}}{\mu\left( {\nu + \omega + \mu} \right)},\frac{\nu\text{Π}}{\mu\left( {\nu + \omega + \mu} \right)},0,0,0} \right).} \\
\end{array}$$

The stability of $\mathcal{E}_{0}$ can be established by calculating the reproduction number $\mathcal{R}_{0}$ using the next generation operator method on system (2). Taking *C*, and *I* as the infected compartments and then using the notation in ([@bib60]), the Jacobian *F* and *V* matrices for new infectious terms and the remaining transfer terms, respectively, are defined as:$$F = \begin{pmatrix}
\frac{\eta\beta S^{\text{**}} + \left( {1 - \varepsilon} \right)\eta\beta V^{\text{**}}}{S^{\text{**}} + V^{\text{**}}} & \frac{\beta S^{\text{**}} + \left( {1 - \varepsilon} \right)\beta V^{\text{**}}}{S^{\text{**}} + V^{\text{**}}} \\
0 & 0 \\
\end{pmatrix},\ \ V = \begin{pmatrix}
{\sigma + \gamma_{C} + \mu} & 0 \\
{- \sigma} & {\gamma_{I} + \mu + \delta} \\
\end{pmatrix}.$$

Therefore, the reproduction number is$$\begin{array}{l}
{\mathcal{R}_{0} = \rho\left( {FV^{- 1}} \right) = \frac{\beta\left\lbrack \eta\left( {\gamma_{I} + \mu + \delta} \right) + \sigma \right\rbrack\left\lbrack S^{\text{**}} + \left( {1 - \varepsilon} \right)V^{\text{**}} \right\rbrack}{\left( {S^{\text{**}} + V^{\text{**}}} \right)\left( {\sigma + \gamma_{C} + \mu} \right)\left( {\gamma_{I} + \mu + \delta} \right)},} \\
{\mathcal{R}_{0} = \rho\left( {FV^{- 1}} \right) = \frac{\beta\left\lbrack \eta\left( {\gamma_{I} + \mu + \delta} \right) + \sigma \right\rbrack\left\lbrack \omega + \mu + \nu\left( {1 - \varepsilon} \right) \right\rbrack}{\left( {\nu + \omega + \mu} \right)\left( {\sigma + \gamma_{C} + \mu} \right)\left( {\gamma_{I} + \mu + \delta} \right)}.} \\
\end{array}$$where, *ρ* is the spectral radius.

The expression $\mathcal{R}_{0}$ is the number of secondary infections in completely susceptible population due to infections from one introduced infectious individual with meningitis. Further, using Theorem 2 in ([@bib60]), the following result is established.Lemma B.1*The disease-free equilibrium (DFE) of the meningitis model (*2*) is locally asymptotically stable (LAS) if* $\mathcal{R}_{0} < 1$ *and unstable if* $\mathcal{R}_{0} > 1$*.*

C. Existence of endemic equilibria of the meningitis model (2) {#appsec2}
==============================================================

Let,$$\mathcal{E}_{1} = \left( {S^{\text{**}},V^{\text{**}},C^{\text{**}},I^{\text{**}},R^{\text{**}}} \right)$$denote the endemic equilibrium of the meningitis model (2) where$$\begin{array}{l}
{S^{\text{**}} = \frac{\pi k_{5}k_{4}k_{3}\left\lbrack \left( {1 - \varepsilon} \right)\lambda + k_{2} \right\rbrack}{a_{1}\lambda^{2} + a_{2}\lambda + a_{3}};} \\
{V^{\text{**}} = \frac{\pi k_{5}k_{4}\nu k_{3}}{a_{1}\lambda^{2} + a_{2}\lambda + a_{3}};} \\
{C^{\text{**}} = \frac{\lambda\pi k_{5}k_{4}\left( {1 - \varepsilon} \right)\left( {\lambda + k_{2} + \nu} \right)}{a_{1}\lambda^{2} + a_{2}\lambda + a_{3}};} \\
{I^{\text{**}} = \frac{\lambda\sigma\pi k_{5}\left( {1 - \varepsilon} \right)\left( {\lambda + k_{2} + \nu} \right)}{a_{1}\lambda^{2} + a_{2}\lambda + a_{3}};} \\
{R^{\text{**}} = \frac{\lambda\pi\left( {1 - \varepsilon} \right)\left( {\lambda + k_{2} + \nu} \right)\left( {\gamma_{C}k_{4} + \gamma_{I}\sigma} \right)}{a_{1}\lambda^{2} + a_{2}\lambda + a_{3}};} \\
\end{array}$$where, $a_{1} = \left( {1 - \varepsilon} \right)\left\lbrack k_{5}k_{4}k_{3} - \kappa\left( {\gamma_{C}k_{4} + \gamma_{I}\sigma} \right) \right\rbrack$, $a_{2} = k_{5}k_{4}k_{3}\left\lbrack k_{2} + k_{1}\left( {1 - \varepsilon} \right) \right\rbrack - \kappa\left( {\gamma_{C}k_{4} + \gamma_{I}\sigma} \right)\left\lbrack k2 + \nu\left( {1 - \varepsilon} \right) \right\rbrack$, $a_{3} = k_{5}k_{4}k_{3}\left( {k_{1}k_{2} - \nu\omega} \right)$, with $k_{1} = \nu + \mu,\ k_{2} = \omega + \mu,\ k_{3} = \sigma + \gamma_{C} + \mu,$ $k_{4} = \gamma_{I} + \mu + \gamma,\ k_{5} = \mu + \kappa,$ and$$\lambda^{\text{**}} = \frac{\beta\left( {\eta C^{\text{**}} + I^{\text{**}}} \right)}{N^{\text{**}}}.$$

Substituting the expression in (C-1) into (C-2), we obtain the following quadratic polynomial after some computations$$b_{1}\left( \lambda^{\text{**}} \right)^{2} + b_{2}\lambda^{\text{**}} + b_{3} = 0,$$where$$\begin{array}{l}
{b_{1} = \text{Π}\left( {1 - \varepsilon} \right)\left\lbrack k_{5}\left( {\sigma + k_{4}} \right) + \gamma_{C}k_{4} + \gamma_{I}\sigma \right\rbrack,} \\
{b_{2} = \text{Π}\left\{ {k_{5}\left\lbrack \left( {\sigma + k_{4}} \right)\left\lbrack k_{2} + \nu\left( {1 - \varepsilon} \right) \right\rbrack + k_{3}k_{4}\left( {1 - \varepsilon} \right) \right\rbrack + \left( {\gamma_{C}k_{4} + \gamma_{I}\sigma} \right)\left\lbrack k_{2} + \nu\left( {1 - \varepsilon} \right) \right\rbrack} \right\}} \\
{- \beta\text{Π}k_{5}\left( {1 - \varepsilon} \right)\left( {\sigma + \eta k_{4}} \right);} \\
{b_{3} = k_{5}k_{4}k_{3}\left( {k_{2} + \nu} \right)\left( {1 - \mathcal{R}_{0}} \right).} \\
\end{array}$$

From polynomial (C-3), we see that the coefficient $b_{1} > 0$. Further, coefficient $b_{3} < 0$ whenever $\mathcal{R}_{0} > 1$. Thus, the signs of $b_{2}$ determines the number of possible positive real roots the polynomial (C-3) can have. This can be investigated using the Descartes Rule of Signs on the quadratic polynomial $g\left( x \right) = c_{1}x^{2} + c_{2}x + c_{3}$, given in (C-3) (with $x = \lambda^{\text{**}},c_{1} = a_{1},\ c_{2} = a_{2},\ c_{3} = a_{3}$). The various possibilities for the roots of $g\left( x \right)$ are tabulated in [Table 5](#dtbl1){ref-type="table"}.Table 5Number of Possible Positive Real Roots of $g\left( x \right)$ when $\mathcal{R}_{0} < 1$ and $\mathcal{R}_{0} > 1$.Table 5Cases$c_{1}$$c_{2}$$c_{3}$$\mathcal{R}_{0}$Number of sign changesNo of possible positive real roots(endemic equilibrium)1+++$\mathcal{R}_{0} < 1$00++--$\mathcal{R}_{0} > 1$112+--+$\mathcal{R}_{0} < 1$20,2+----$\mathcal{R}_{0} > 1$11

The following results ([Theorem C.1](#enun_Theorem_C_1){ref-type="statement"} and [Lemma C.2](#enun_Lemma_C_2){ref-type="statement"}) follow from the various possible combinations for the roots of $g\left( x \right)$ in Table 5.Theorem C.1*The meningitis model (*2*) has a unique endemic equilibrium if* $\mathcal{R}_{0} > 1$ *and whenever Cases 1 and 2 are satisfied.*

The existence of multiple endemic equilibria when $\mathcal{R}_{0} < 1$ (shown in Table 5) indicates the possibility of backward bifurcation ([@bib5], [@bib2]; [@bib10]; [@bib13]; [@bib20]; [@bib21]; [@bib24]; [@bib52], [@bib53]), a phenomenon where the disease-free equilibrium co-exist with a stable endemic equilibrium when the associated reproduction number ($\mathcal{R}_{0}$) is less than one.Lemma C.2*The meningitis model (*2*) has at least one positive endemic equilibrium whenever* $\mathcal{R}_{0} > 1$*, and could have zero or two positive endemic equilibria whenever* $\mathcal{R}_{0} < 1$*.*

D. Backward bifurcation analysis of the meningitis model (2) {#appsec3}
============================================================

The phenomenon of backward bifurcation is shown using the concept of centre manifold theory on system (2). First, we make the following changes in variables by setting $S = x_{1}$, $V = x_{2}$, $C = x_{3}$, $I = x_{4}$, and $R = x_{5}$. Furthermore, employing the vector notation $\mathbf{x} = \left( {\mathbf{x}_{1},\mathbf{x}_{2},\mathbf{x}_{3},\mathbf{x}_{4},\mathbf{x}_{5}} \right)$, the meningitis model (2) with vaccination can be reformulated in the form $dx/dt = F\mathbf{x}$, with $F = \left( {f_{1},f_{2},f_{3},f_{4},f_{5}} \right)^{T}$ as given below$$\begin{array}{l}
{\frac{dx_{1}}{dt} = f_{1} = \pi - \frac{\beta\left( {\eta x_{3} + x_{4}} \right)x_{1}}{x_{1} + x_{2} + x_{3} + x_{4} + x_{5}} - k_{1}x_{1} + \omega x_{2} + \kappa x_{5}} \\
\left. \frac{dx_{2}}{dt} = f_{2} = \nu x_{1} - \frac{\beta\left( {1 - \varepsilon} \right)\left( {\eta x_{3} + x_{4}} \right)x_{2}}{x_{1} + x_{2} + x_{3} + x_{4} + x_{5}} - k_{2}x_{2} \right\rbrack \\
{\frac{dx_{3}}{dt} = f_{3} = \frac{\beta\left( {\eta x_{3} + x_{4}} \right)x_{1}}{x_{1} + x_{2} + x_{3} + x_{4} + x_{5}} + \frac{\left( {1 - \varepsilon} \right)\beta\left( {\eta x_{3} + x_{4}} \right)x_{2}}{x_{1} + x_{2} + x_{3} + x_{4} + x_{5}} - k_{3}x_{3}} \\
{\frac{dx_{4}}{dt} = f_{4} = \sigma x_{3} - k_{4}x_{4}} \\
{\frac{dx_{5}}{dt} = f_{5} = \gamma_{C}x_{3} + \gamma_{I}x_{4} - k_{5}x_{5},} \\
\end{array}$$

The Jacobian of system (D-1) evaluated at the disease-free equilibrium, $\mathcal{E}_{0}$, is given by$$J_{1} = \begin{pmatrix}
{- k_{1}} & \omega & {- \frac{\beta\eta x_{1}}{x_{1} + x_{2}}} & {- \frac{\beta x_{1}}{x_{1} + x_{2}}} & \kappa \\
\nu & {- k_{2}} & {- \frac{\left( {1 - \varepsilon} \right)\beta\eta x_{2}}{x_{1} + x_{2}}} & {- \frac{\left( {1 - \varepsilon} \right)\beta x_{2}}{x_{1} + x_{2}}} & 0 \\
0 & 0 & {\frac{\left\lbrack \beta\eta x_{1} + \left( {1 - \varepsilon} \right)\beta\eta x_{2} \right\rbrack}{x_{1} + x_{2}} - k_{3}} & \frac{\left\lbrack \beta x_{1} + \left( {1 - \varepsilon} \right)\beta x_{2} \right\rbrack}{x_{1} + x_{2}} & 0 \\
0 & 0 & \sigma & {- k_{4}} & 0 \\
0 & 0 & \gamma_{C} & \gamma_{I} & {- k_{5}} \\
\end{pmatrix}$$

Consider the case $\mathcal{R}_{0} = 1$. Suppose that *β* is chosen as a bifurcation parameter. Setting $\mathcal{R}_{0} = 1$ and solving for *β* using the expression for $\mathcal{R}_{0}$ gives$$\beta^{\text{*}} = \frac{\left( {x_{1}^{\text{*}} + x_{2}^{\text{*}}} \right)k_{3}k_{4}}{\left( {\eta k_{4} + \sigma} \right)x_{1}^{\text{*}} + \left( {1 - \varepsilon} \right)x_{2}^{\text{*}}}.$$

The Jacobian matrix $J_{1}$ evaluated at $\beta = \beta^{\text{*}}$ has a simple zero eigenvalue with the other eigenvalues having negative real parts. Hence the centre manifold theorem can be applied to analyze the dynamics of (D-1) near $\beta = \beta^{\text{*}}$.

Computing the right and the left eigenvector of $J_{1}$, denoted respectively by ${\mathbf{w} = \left\lbrack \mathbf{w}_{1},\mathbf{w}_{2},\mathbf{w}_{3},\mathbf{w}_{4},\mathbf{w}_{5} \right\rbrack}^{\mathbf{T}}$ and $\mathbf{v} = \left\lbrack \mathbf{v}_{1},\mathbf{v}_{2},\mathbf{v}_{3},\mathbf{v}_{4},\mathbf{v}_{5} \right\rbrack$, we have$$\begin{array}{l}
{w_{1} = - \frac{1}{k_{1}}\left\lbrack \omega w_{2} - \frac{\beta\eta x_{1}^{\text{*}}w_{3}}{x_{1}^{\text{*}} + x_{2}^{\text{*}}} - \frac{\beta x_{1}^{\text{*}}w_{4}}{x_{1}^{\text{*}} + x_{2}^{\text{*}}} + \kappa w_{5} \right\rbrack,} \\
{w_{4} = \frac{\sigma w_{3}}{k_{4}},\ w_{5} = \frac{\left( {\gamma_{C}w_{3} + \gamma_{I}w_{4}} \right)}{k_{5}},\ w_{2},\ w_{3} > 0.} \\
\end{array}$$and$$\begin{array}{l}
{v_{1} = \frac{\nu v_{2}}{k_{1}},\ \ v_{2}\  = \ v_{3}\  = \ 1,\ v_{5}\  = \ \frac{\kappa v_{1}}{k_{5}},} \\
{v_{4} = \frac{1}{k_{4}}\left\lbrack - \frac{\beta x_{1}^{\text{*}}v_{1}}{x_{1}^{\text{*}} + x_{2}^{\text{*}}} - \frac{\left( {1 - \varepsilon} \right)\beta x_{2}^{\text{*}}v_{2}}{x_{1}^{\text{*}} + x_{2}^{\text{*}}} + \frac{\left\lbrack \beta x_{1}^{\text{*}} + \left( {1 - \varepsilon} \right)\beta x_{2}^{\text{*}} \right\rbrack v_{3}}{x_{1}^{\text{*}} + x_{2}^{\text{*}}} + \gamma_{I}v_{5} \right\rbrack.} \\
\end{array}$$

Using the result from Theorem 4.1 by Castillo-Chavez and Song ([@bib14]), we calculate the coefficients *a* and *b* as$$a = - \frac{2\beta\left( {\eta w_{3} + w_{4}} \right)\left( {v_{2} - v_{1}} \right)\left\lbrack x_{1}^{\text{*}}\left( {w_{2} + w_{3} + w_{4} + w_{5}} \right) - w_{1}x_{2}^{\text{*}} \right\rbrack}{\left( {x_{1}^{\text{*}} + x_{2}^{\text{*}}} \right)^{2}}.$$

The coefficient *b* is given as follows:$$b = \frac{\left( {w_{4} + \eta w_{3}} \right)\left\lbrack x_{1}^{\text{*}}\left( {v_{3} - v_{1}} \right) + x_{2}^{\text{*}}\left( {1 - \varepsilon} \right)\left( {v_{3} - v_{2}} \right) \right\rbrack}{x_{1}^{\text{*}} + x_{2}^{\text{*}}}.$$

The coefficient *b* is positive since $v_{3} > v_{1}$ and $v_{3} = v_{2}$; the presence of backward bifurcation in model (2) is determined by the sign of coefficient *a*.

E. Stability analysis of the pre-intervention model (3) {#appsec4}
=======================================================

Local stability of the DFE {#appsec4.1}
--------------------------

The disease free equilibrium (DFE) of the meningitis pre-intervention model (3) is given by$$\begin{matrix}
{{\widetilde{\mathcal{E}}}_{0} = \left( {S^{\text{*}},\ C^{\text{*}},\ I^{\text{*}},\ R^{\text{*}}} \right)} \\
{= \left( {\frac{\text{Π}}{\mu},0,0,0} \right).} \\
\end{matrix}$$

The stability of ${\widetilde{\mathcal{E}}}_{0}$ is established by calculating the reproduction number ${\widetilde{\mathcal{R}}}_{0}$ using the next generation operator method on system (3) as in [Appendix B](#appsec2){ref-type="sec"}. Taking *C*, and *I* as the infected compartments, the Jacobian $F_{P}$ and $V_{P}$ matrices for new infectious terms and the remaining transfer terms, respectively, are defined as:$$F_{P} = \begin{pmatrix}
{\eta\beta} & \beta \\
0 & 0 \\
\end{pmatrix},\quad\quad V_{P} = \begin{pmatrix}
{\sigma + \gamma_{C} + \mu} & 0 \\
{- \sigma} & {\gamma_{I} + \mu + \delta} \\
\end{pmatrix}.$$

Therefore, the reproduction number is$${\widetilde{\mathcal{R}}}_{0} = \rho\left( {F_{P}V_{P}^{- 1}} \right) = \frac{\beta\left\lbrack \eta\left( {\gamma_{I} + \mu + \delta} \right) + \sigma \right\rbrack}{\left( {\sigma + \gamma_{C} + \mu} \right)\left( {\gamma_{I} + \mu + \delta} \right)},$$

Using Theorem 2 in ([@bib60]), the following result is established.Lemma E.1*The disease-free equilibrium (DFE) of the meningitis pre-intervention model (*3*) is locally asymptotically stable (LAS) if* ${\widetilde{\mathcal{R}}}_{0} < 1$ *and unstable if* ${\widetilde{\mathcal{R}}}_{0} > 1$*.*

Global stability of DFE {#appsec4.2}
-----------------------

Theorem E.2*The DFE of the meningitis pre-intervention model (*3*) is globally asymptotically stable whenever* ${\widetilde{\mathcal{R}}}_{0} < 1$*.*ProofThe proof is based on using a comparison theorem. The equations for the infected components in (3) can be written in terms of$$\begin{pmatrix}
\frac{dC\left( t \right)}{dt} \\
\frac{dI\left( t \right)}{dt} \\
\end{pmatrix} = \left( {F_{P} - V_{P}} \right)\begin{pmatrix}
{C\left( t \right)} \\
{I\left( t \right)} \\
\end{pmatrix} - MQ,$$where, $M = 1 - S/N$, the matrices $F_{P}$, $V_{P}$, and *Q* are non-negative matrices given, respectively, by$$F_{P} = \begin{pmatrix}
{\beta\eta} & \beta \\
0 & 0 \\
\end{pmatrix},\ \ \ \ \ \ V_{P} = \begin{pmatrix}
{k3} & 0 \\
{- \sigma} & {k4} \\
\end{pmatrix},\ \ \ \ \ Q = \begin{pmatrix}
{\beta\eta} & \beta \\
0 & 0 \\
\end{pmatrix}.$$

Thus, since $S\left( t \right) \leq N\left( t \right)$ in $\text{Ω}_{P}$, for all $t \geq 0$, it follows from (E-1) that$$\begin{pmatrix}
\frac{dC\left( t \right)}{dt} \\
\frac{dI\left( t \right)}{dt} \\
\end{pmatrix} \leq \left( {F_{P} - V_{P}} \right).$$

Using the fact that the eigenvalues of the matrix $F_{P} - V_{P}$ all have negative real parts (see the local stability result given in [Lemma E.1](#enun_Lemma_E_1){ref-type="statement"}, where $\rho\left( {F_{P}V_{P}^{- 1}} \right) < 1$ if ${\widetilde{\mathcal{R}}}_{0} < 1$ which is equivalent to $F_{P} - V_{P}$ having eigenvalues with negative real parts when ${\widetilde{\mathcal{R}}}_{0} < 1$ ([@bib60])), it follows that the linearized differential inequality system (E-2) is stable whenever ${\widetilde{\mathcal{R}}}_{0} < 1$. Consequently, $\left. \left( {C\left( t \right),I\left( t \right)} \right)\rightarrow\left( 0,0 \right) \right.$ as $\left. t\rightarrow\infty \right.$. Thus, by comparison theorem ([@bib35]; [@bib56]), $\left( {C\left( t \right),I\left( t \right)} \right)$ $\left. \rightarrow\left( 0,0 \right) \right.$ as $\left. t\rightarrow\infty \right.$. Substituting $C = I = 0$ in the third, and fourth equations of the meningitis model (3) gives $\left. S\left( t \right)\rightarrow S^{\text{*}},\ R\left( t \right)\rightarrow 0 \right.$. Hence, $\left. \left( {S\left( t \right),C\left( t \right),I\left( t \right),R\left( t \right)} \right)\rightarrow\left( {S^{\text{*}},0,0,0} \right) \right.$ as $\left. t\rightarrow\infty \right.$ for ${\widetilde{\mathcal{R}}}_{0} < 1$. Hence, the DFE ${\widetilde{\mathcal{E}}}_{0}$ is GAS in $\text{Ω}_{P}$ if ${\widetilde{\mathcal{R}}}_{0} < 0$.

F. Existence of endemic equilibrium of the pre-intervention model (3) {#appsec5}
=====================================================================

Let,$${\widetilde{\mathcal{E}}}_{1} = \left( {S^{\text{**}},C^{\text{**}},I^{\text{**}},R^{\text{**}}} \right)$$denote the endemic equilibrium of the pre-intervention model (3) where$$\begin{array}{l}
{S^{\text{**}} = \frac{k_{5}k_{4}k_{3}\pi}{\lambda\left\lbrack k_{5}k_{4}k_{3} - \kappa\left( {\gamma_{C}k_{4} + \gamma_{I}\sigma} \right) \right\rbrack + k_{5}k_{4}k_{3}k_{1}};} \\
{C^{\text{**}} = \frac{\lambda k_{5}k_{4}\pi}{\lambda\left\lbrack k_{5}k_{4}k_{3} - \kappa\left( {\gamma_{C}k_{4} + \gamma_{I}\sigma} \right) \right\rbrack + k_{5}k_{4}k_{3}k_{1}};} \\
{I^{\text{**}} = \frac{\sigma\lambda k_{5}\pi}{\lambda\left\lbrack k_{5}k_{4}k_{3} - \kappa\left( {\gamma_{C}k_{4} + \gamma_{I}\sigma} \right) \right\rbrack + k_{5}k_{4}k_{3}k_{1}};} \\
{R^{\text{**}} = \frac{\lambda\left\lbrack \left( {\gamma_{C}k_{4} + \gamma_{I}\sigma} \right)\pi \right\rbrack}{\lambda\left\lbrack k_{5}k_{4}k_{3} - \kappa\left( {\gamma_{C}k_{4} + \gamma_{I}\sigma} \right) \right\rbrack + k_{5}k_{4}k_{3}k_{1}};} \\
\end{array}$$with$$\lambda^{\text{**}} = \frac{\beta\left( {\eta C + I} \right)}{N}.$$

Substituting the expression in [(F-2)](#fdF_2){ref-type="disp-formula"}, [(F-3)](#fdF_3){ref-type="disp-formula"}, we obtain after some computations the polynomial$$\begin{array}{l}
{d_{1}\lambda^{\text{**}} + d_{2}\  = \ 0,} \\
{\lambda^{\text{**}}\  = \  - \frac{c_{2}}{c_{1}}} \\
\end{array}$$where$$\begin{array}{l}
{d_{1} = \left( {k_{5}k_{4}\pi + \sigma k_{5}\pi + \left( {\gamma_{C}k_{4} + \gamma_{I}\sigma} \right)\pi} \right),} \\
{d_{2} = k_{5}k_{4}k_{3}\pi\left\lbrack {1 - \frac{\beta\left( {\eta k_{4} + \sigma} \right)}{k_{4}k_{3}}} \right\rbrack} \\
{= k_{5}k_{4}k_{3}\pi\left( {1 - {\widetilde{\mathcal{R}}}_{0}} \right).} \\
\end{array}$$

It follows from (F-0) that $\lambda^{\text{**}} > 0$ if and only if ${\widetilde{\mathcal{R}}}_{0} > 1$. Furthermore, $\lambda^{\text{**}} \leq 0$ if ${\widetilde{\mathcal{R}}}_{0} \leq 1$ ( $\lambda^{\text{**}} = 0$ corresponds to the DFE, and $\lambda^{\text{**}} < 0$ is biologically meaningless). Thus, the model (3) has a unique EEP whenever ${\widetilde{\mathcal{R}}}_{0} > 1$. This result is summarized below:Theorem F.1*The meningitis model (*3*) has a unique endemic equilibrium whenever* ${\widetilde{\mathcal{R}}}_{0} > 1$*, and no endemic equilibrium otherwise.*

G. Characterization of optimal controls {#appsec6}
=======================================

We seek to find optimal controls $u_{m}^{\text{*}},u_{v}^{\text{*}}$, such that$$J\left( {u_{m}^{\text{*}},u_{v}^{\text{*}}} \right) = \underset{\mathcal{U}}{\text{min}}\left\{ {J\left( {u_{m},u_{v}} \right)} \right\}$$where the control set,$$\mathcal{U} = \left\{ \left( {u_{m}\left( t \right),u_{v}\left( t \right)} \right),\ \left( {u_{m},u_{v}} \right):\left\lbrack 0,t_{f} \right\rbrack\rightarrow\ \left\lbrack 0,1 \right\rbrack,\ \ \text{is}\ \text{Lebesgue}\ \text{measurable} \right\}.$$

Control characterizations {#appsec6.1}
-------------------------

The necessary conditions that an optimal control pair must satisfy come from Pontryagin\'s Maximum Principle ([@bib47]). This principle converts (5) and (6) into a problem of minimizing pointwise a Hamiltonian *H*, with respect to the controls ($u_{m}\left( t \right)$ and $u_{v}\left( t \right)$). First we formulate the Hamiltonian from the cost functional (6) and the governing dynamics (5) to obtain the optimality conditions.$$\begin{array}{l}
{H = A_{1}C + A_{2}I + A_{3}u_{m}^{2} + A_{4}u_{v}^{2} + \lambda_{S}\left\lbrack \text{Π} + \omega V + \kappa R - \lambda\left( t \right)S - u_{v}\left( t \right)S - \mu S \right\rbrack} \\
{+ \ \lambda_{V}\left\lbrack u_{v}\left( t \right)S - \left( {1 - \varepsilon} \right)\lambda\left( t \right)V - \left( {\omega + \mu} \right)V \right\rbrack} \\
{+ \ \lambda_{C}\left\{ {\lambda\left( t \right)S + \left( {1 - \varepsilon} \right)\lambda\left( t \right)V - \left\lbrack \sigma + \gamma_{C} + \mu \right\rbrack C} \right\}} \\
{+ \ \lambda_{I}\left\{ {\sigma C - \left( {\gamma_{I} + \mu + \delta} \right)I} \right\} + \lambda_{R}\left\lbrack \gamma_{C}C + \gamma_{I}I - \left( {\mu + \kappa} \right)R \right\rbrack,} \\
\end{array}$$where $\lambda_{S},\ \lambda_{V},\ \lambda_{C},\ \lambda_{I},\ \lambda_{R}$ are the associated adjoints for the states $S,\ V,\ C,\ I,\ R$. The system of adjoint equations is found by taking the appropriate partial derivatives of the Hamiltonian (G-2) with respect to the associated state and control variables.Theorem G.1*Given an optimal control pair (*$u_{m}^{\text{*}},u_{v}^{\text{*}}$*) and solutions* $S^{\text{*}},\ V^{\text{*}},\ C^{\text{*}},\ I^{\text{*}},\ R^{\text{*}}$ *of the corresponding state system (*5*) that minimizes* $J\left( {u_{m}^{\text{*}},u_{v}^{\text{*}}} \right)$ *over* $\mathcal{U}$*. Then there exists adjoint variables* $\lambda_{S},\ \lambda_{V},\ \lambda_{C},\ \lambda_{I},\lambda_{R}$ *satisfying*$$\begin{matrix}
{- \frac{d\lambda_{i}}{dt} = \frac{\partial H}{\partial i}} & \\
\end{matrix}$$and with transversality conditions$$\begin{matrix}
{\lambda_{i}\left( t_{f} \right) = 0,\ \ where\ \ i = S,\ V,\ C,\ I,\ R.} & & \\
\end{matrix}$$

The optimality conditions is given as$$\frac{\partial H}{\partial u_{j}} = 0,\ \ \ \ j = 1,2$$in the interior of the control set $\mathcal{U}$. Furthermore, the control pair $\left( {u_{m}^{\text{*}},u_{v}^{\text{*}}} \right)$ is given as$$\begin{array}{l}
{u_{m}^{\text{*}} = \text{min}\left\{ {b_{m},\text{max}\left\lbrack {a_{m},\ \ \frac{\beta\left\lbrack S^{\text{*}}\left( {\lambda_{C}^{\text{*}} - \lambda_{S}^{\text{*}}} \right) + \left( {1 - \varepsilon} \right)V^{\text{*}}\left( {\lambda_{C}^{\text{*}} - \lambda_{V}^{\text{*}}} \right) \right\rbrack\left( {\eta C^{\text{*}} + I^{\text{*}}} \right)}{2A_{3}N^{\text{*}}}} \right\rbrack} \right\},} \\
{u_{v}^{\text{*}} = \text{min}\left\{ {b_{v},\text{max}\left\lbrack {a_{v},\ \ \frac{S^{\text{*}}\left( {\lambda_{S}^{\text{*}} - \lambda_{V}^{\text{*}}} \right)}{2A_{4}}} \right\rbrack} \right\}.} \\
\end{array}$$ProofThe existence of an optimal control is guaranteed using the result by Fleming and Rishel ([@bib23]). Thus, the differential equations governing the adjoint variables are obtained by the differentiation of the Hamiltonian function, evaluated at the optimal controls. Thus, the adjoint system can be written as:$$- \frac{d\lambda_{S}}{dt} = \ \frac{\partial H}{\partial S},\ \ \ \ \lambda_{S}\left( t_{f} \right) = 0,$$$$- \frac{d\lambda_{V}}{dt} = \ \frac{\partial H}{\partial V},\ \ \ \lambda_{V}\left( t_{f} \right) = 0,$$$$- \frac{d\lambda_{C}}{dt} = \frac{\partial H}{\partial C},\ \ \ \ \lambda_{C}\left( t_{f} \right) = 0,$$$$- \frac{d\lambda_{I}}{dt} = \frac{\partial H}{\partial I},\ \ \ \ \lambda_{I}\left( t_{f} \right) = 0,$$$$- \frac{d\lambda_{R}}{dt} = \frac{\partial H}{\partial R},\ \ \ \ \lambda_{R}\left( t_{f} \right) = 0,$$evaluated at the optimal controls and corresponding state variables, results in the stated adjoint system (G-2) and (G-3). Furthermore, differentiating the Hamiltonian function with respect to the control variables in the interior of the control set and then solving for controls $\left( {u_{m}^{\text{*}},u_{v}^{\text{*}}} \right)$ result in the optimality conditions given as$$\begin{array}{l}
{\frac{\partial H}{\partial u_{m}} = 2A_{3}u_{m} - \frac{\beta\left\lbrack S^{\text{*}}\left( {\lambda_{C}^{\text{*}} - \lambda_{S}^{\text{*}}} \right) + \left( {1 - \varepsilon} \right)V^{\text{*}}\left( {\lambda_{C}^{\text{*}} - \lambda_{V}^{\text{*}}} \right) \right\rbrack\left( {\eta C^{\text{*}} + I^{\text{*}}} \right)}{N^{\text{*}}} = 0,} \\
{\frac{\partial H}{\partial u_{v}} = 2A_{4}u_{v} - S^{\text{*}}\left( {\lambda_{S}^{\text{*}} - \lambda_{V}^{\text{*}}} \right) = 0.} \\
\end{array}$$Solving for $u_{m}^{\text{*}}$ and $u_{v}^{\text{*}}$, we have,$$u_{m}^{\text{*}} = \frac{\beta\left\lbrack S^{\text{*}}\left( {\lambda_{C}^{\text{*}} - \lambda_{S}^{\text{*}}} \right) + \left( {1 - \varepsilon} \right)V^{\text{*}}\left( {\lambda_{C}^{\text{*}} - \lambda_{V}^{\text{*}}} \right) \right\rbrack\left( {\eta C^{\text{*}} + I^{\text{*}}} \right)}{2A_{3}N^{\text{*}}},$$$$u_{v}^{\text{*}} = \frac{S^{\text{*}}\left( {\lambda_{S}^{\text{*}} - \lambda_{V}^{\text{*}}} \right)}{2A_{4}}.$$Using the bounds on the controls, the characterization (G-4) can be derived. ∎Remark 1*Due to the a priori boundedness of the state and adjoint functions and the resulting Lipschitz structure of the ODE\'s, the uniqueness of the optimal control for small time (*$t_{f}$*) was obtained. The uniqueness of the optimal control quintuple follows from the uniqueness of the optimality system, which consists of (5) and (G-2), (G-3) with characterization (G-4). The restriction on the length of the time interval is to guarantee the uniqueness of the optimality system, the smallness in the length of time is due to the opposite time orientations of (5), (G-2), and (G-3); the state problem has initial values, and the adjoint problem has final values. This restriction is very common in control problems (see* ([@bib1]; [@bib7]; [@bib6]; [@bib30]; [@bib31]; [@bib32]; [@bib33])*).*
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